|
ResMed Inc. is a digital health company that designs and manufactures cloud-connected medical devices and software solutions for sleep and breathing health disorders. The company operates in two segments: Sleep and Breathing Health, which includes CPAP systems for obstructive sleep apnea, ventilators, diagnostic products, and mask systems; and Residential Care Software, which provides care management platforms for senior living and home health providers. ResMed serves patients, healthcare professionals, and residential care facilities globally. Key subsidiaries and acquired businesses include Noctrix Health for restless legs syndrome treatment, VirtuOx for independent diagnostic testing, Brightree for durable medical equipment workflow automation, and MEDIFOX DAN for care management in Germany. The company was formed in 1989 and commercialized the first successful non-invasive CPAP treatment for obstructive sleep apnea. Summarised from the company's own disclosures, fiscal year ended Aug 2026 |
Industry Medical Devices | Homepage resmed.com |
| Sector Healthcare | IR page — | |
|
Tags
sleep apnea, cpap therapy, respiratory care, home healthcare, digital health, cloud-connected devices, residential care software, diagnostic testing, chronic disease management, medical devices, AirFit 20 Series, Noctrix Health, VirtuOx, Brightree, MEDIFOX DAN, MatrixCare, Healthcare First, Citus
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 33.331B |
| Market cap (USD) | $ 33.331B |
| P/E | 21.58 |
| PEG | 1.12 |
| P/BV | 5.60 |
| P/S | 5.81 |
| P/OCF | 18.82 |
| P/FCF | 20.72 |
| Dividend yield | 1.0% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 24.3% |
| ROI | 21.8% |
| ROIC | 21.4% |
| Profit margin | 26.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 19.3% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | 4.2% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 53 |
| Quality score | 47.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
+1 858-221-3304 +1 619-510-1281
[email protected] [email protected]
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
• Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis
• Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91
• Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, October 29, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business,” said Resmed’s Chairman and CEO, Mick Farrell. “Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.
October 29, 2026 4:05pm EDT
Related Documents
Earnings WebcastAudio Transcript
- Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis
- Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91
- Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business,” said Resmed's Chairman and CEO, Mick Farrell. “Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
Other Business and Operational Highlights
- Closed the previously announced divestiture of the MatrixCare business.
- Announced the U.S. launch of the AirTouch F40, the newest addition to Resmed’s growing portfolio of fabric CPAP masks.
- Partnered with Eight Sleep to connect its technology with Resmed sleep insights for people in the U.S. and Australia, and with 23XI Racing NASCAR driver Tyler Reddick, following his sleep apnea diagnosis, to help others recognize the signs and seek treatment.
- Announced appointment of Carol Burt as Lead Director, effective November 15, 2026, after the planned retirement of Director Ron Taylor.
Financial Results and Operating Metrics
(Unaudited; $ in millions, except for per share amounts)
Scroll to view ↔
| Three Months Ended | |||||||||||||
| September 30, 2026 | September 30, 2025 | % Change | Constant Currency_(A)_ | ||||||||||
| Revenue | $ | 1,415 | $ | 1,336 | 6 | % | 6 | % | |||||
| Gross margin**(D)** | 61.5 | % | 61.2 | % | 30 bps | ||||||||
| Non-GAAP gross margin_(B)_ | 62.5 | % | 62.0 | % | 50 bps | ||||||||
| Research and development expenses**(D)** | 103 | 89 | 15 | 13 | |||||||||
| Non-GAAP research and development expenses_(B)_ | 102 | 87 | 16 | 14 | |||||||||
| Selling, general, and administrative expenses**(D)** | 315 | 282 | 12 | 11 | |||||||||
| Non-GAAP selling, general, and administrative expenses_(B)_ | 276 | 259 | 6 | 6 | |||||||||
| Income from operations | 453 | 447 | 1 | ||||||||||
| Operating margin | 32.0 | % | 33.4 | % | (140) bps | ||||||||
| Non-GAAP income from operations_(B)_ | 506 | 482 | 5 | ||||||||||
| Non-GAAP operating margin_(B)_ | 35.8 | % | 36.1 | % | (30) bps | ||||||||
| Net income | 418 | 349 | 20 | ||||||||||
| Non-GAAP net income_(B)_ | 418 | 375 | 12 | ||||||||||
| Diluted earnings per share | $ | 2.92 | $ | 2.37 | 23 | ||||||||
| Non-GAAP diluted earnings per share_(B)_ | $ | 2.91 | $ | 2.55 | 14 | ||||||||
| Operating cash flow | 422 | 457 | (8 | ) | |||||||||
| Free cash flow_(C)_ | 374 | 414 | (10 | ) | |||||||||
- In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Revenue growth on a core constant currency basis, which also excludes the impact of the Noctrix acquisition and the divestiture of the MatrixCare business, was 7%.
- See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
- Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.
- During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses. Prior-period amounts have been reclassified to conform to the current-period presentation. See reconciliation of reclassification of prior-period amounts at the end of the press release.
Discussion of First Quarter Results
All comparisons are to the prior year period unless otherwise noted
- Strong revenue growth: Revenue increased 6% (7% in core constant currency) to approximately $1.4 billion, primarily driven by strong demand across sleep devices and masks and accessories.
- Global momentum: On a core constant currency basis, Americas Sleep and Breathing Health revenue grew 7%, Rest of World Sleep and Breathing Health grew 8%, and Residential Care Software revenue increased 5%.
- Healthy profitability: GAAP gross margin of 61.5%. Non-GAAP gross margin increased 50 basis points to 62.5%, predominantly from productivity pipeline execution.
- Robust earnings growth: GAAP operating margin of 32.0% and GAAP diluted earnings per share of $2.92. Non-GAAP operating margin of 35.8% and non-GAAP diluted earnings per share of $2.91, up 14% year-over-year, predominantly attributable to strong revenue growth and gross margin improvement.
- Strong cash generation: Operating cash flow totaled $422 million and free cash flow totaled $374 million. Proceeds from the sale of MatrixCare and strong cash flows supported $1.0 billion returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.
Fiscal Year 2027 guidance
Scroll to view ↔
| Metric | FY 2027 Guidance as of August 6, 2026 | FY 2027 Guidance as of October 29, 2026 | Change |
| Revenue | Core Constant Currency: 5 - 7% growth | Core Constant Currency: 5 - 7% growth | — |
| Reported: $5.75 - $5.85 Billion | Reported: $5.75 - $5.85 Billion | — | |
| Non-GAAP Diluted EPS | $12.00 - $12.25 | $12.00 - $12.25 | — |
_
Dividend program_
The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 11, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from November 11, 2026, through November 12, 2026, inclusive.
Webcast details
Resmed will discuss its first quarter fiscal year 2027 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com
. Please go to this section of the website and click on the icon for the “Q1 2027 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13762822. The telephone replay will be available until November 12, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, results of operations, new product development, new product launches, new markets for its products, the integration of acquisitions and success of strategic initiatives, including divestitures, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.
– More –
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
Scroll to view ↔
| Three Months Ended | |||||||
| September 30, 2026 | September 30, 2025 | ||||||
| Net revenue | $ | 1,414,814 | $ | 1,335,582 | |||
| Cost of sales (2) | 544,247 | 517,918 | |||||
| Gross profit (2) | 870,567 | 817,664 | |||||
| Research and development (2) | 102,860 | 89,479 | |||||
| Selling, general, and administrative (2) | 314,723 | 281,648 | |||||
| Total operating expenses | 417,583 | 371,127 | |||||
| Income from operations | 452,984 | 446,537 | |||||
| Other income (expenses), net: | |||||||
| Interest (expense) income, net | 16,384 | 8,793 | |||||
| Gain (loss) attributable to equity method investments | 1,884 | 1,489 | |||||
| Gain (loss) on equity investments | 5,719 | (6,190 | ) | ||||
| Other, net | 62,184 | (3,836 | ) | ||||
| Total other income (expenses), net | 86,171 | 256 | |||||
| Income before income taxes | 539,155 | 446,793 | |||||
| Income taxes | 120,742 | 98,257 | |||||
| Net income | $ | 418,413 | $ | 348,536 | |||
| Basic earnings per share | $ | 2.93 | $ | 2.38 | |||
| Diluted earnings per share | $ | 2.92 | $ | 2.37 | |||
| Non-GAAP diluted earnings per share (1) | $ | 2.91 | $ | 2.55 | |||
| Basic shares outstanding | 142,989 | 146,182 | |||||
| Diluted shares outstanding | 143,411 | 146,899 |
Scroll to view ↔
| (1) | See the reconciliation of non-GAAP financial measures in the table at the end of the press release. | |
| (2) | During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses. Prior-period amounts have been reclassified to conform to the current-period presentation. See reconciliation of reclassification of prior-period amounts at the end of the press release. | |
– More –
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
Scroll to view ↔
| September 30, 2026 | June 30, 2026 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,010,742 | $ | 1,469,234 | |||
| Accounts receivable, net | 972,498 | 1,036,233 | |||||
| Inventories | 1,021,358 | 945,805 | |||||
| Prepaid expenses and other current assets | 504,323 | 416,081 | |||||
| Assets held for sale | — | 457,386 | |||||
| Total current assets | $ | 3,508,921 | $ | 4,324,739 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 601,787 | $ | 581,829 | |||
| Operating lease right-of-use assets | 196,688 | 153,167 | |||||
| Goodwill and other intangibles, net | 3,350,913 | 3,362,312 | |||||
| Deferred income taxes and other non-current assets | 553,502 | 543,903 | |||||
| Total non-current assets | $ | 4,702,890 | $ | 4,641,211 | |||
| Total assets | $ | 8,211,811 | $ | 8,965,950 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 320,677 | $ | 308,923 | |||
| Accrued expenses | 480,166 | 494,921 | |||||
| Operating lease liabilities, current | 31,527 | 29,141 | |||||
| Deferred revenue | 171,647 | 162,911 | |||||
| Income taxes payable | 160,228 | 98,108 | |||||
| Short-term debt | 159,975 | 259,950 | |||||
| Liabilities held for sale | — | 41,156 | |||||
| Total current liabilities | $ | 1,324,220 | $ | 1,395,110 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 174,209 | $ | 170,951 | |||
| Deferred income taxes | 62,651 | 64,640 | |||||
| Operating lease liabilities, non-current | 169,447 | 137,413 | |||||
| Other long-term liabilities | 283,965 | 213,028 | |||||
| Long-term debt | 249,629 | 399,415 | |||||
| Total non-current liabilities | $ | 939,901 | $ | 985,447 | |||
| Total liabilities | $ | 2,264,121 | $ | 2,380,557 | |||
| Stockholders’ equity | |||||||
| Common stock | $ | 764 | $ | 764 | |||
| Additional paid-in capital | 2,133,418 | 2,190,614 | |||||
| Retained earnings | 7,578,580 | 7,255,121 | |||||
| Treasury stock | (3,633,335 | ) | (2,778,591 | ) | |||
| Accumulated other comprehensive loss | (131,737 | ) | (82,515 | ) | |||
| Total stockholders’ equity | $ | 5,947,690 | $ | 6,585,393 | |||
| Total liabilities and stockholders’ equity | $ | 8,211,811 | $ | 8,965,950 |
– More –
**RESMED INC. AND SUBSIDIARIES
**
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended | |||||||
| September 30, 2026 | September 30, 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 418,413 | $ | 348,536 | |||
| Adjustments to reconcile net income to cash provided by operating activities: | |||||||
| Depreciation and amortization | 41,741 | 47,698 | |||||
| Amortization of right-of-use assets | 10,090 | 9,971 | |||||
| Stock-based compensation costs | 29,475 | 21,160 | |||||
| (Gain) loss attributable to equity method investments | (1,884 | ) | (1,489 | ) | |||
| (Gain) loss on equity investments | (5,719 | ) | 6,190 | ||||
| (Gain) loss on divestment of subsidiaries | (61,784 | ) | — | ||||
| Non-cash restructuring expenses | 6,242 | — | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | 64,839 | 29,970 | |||||
| Inventories | (71,764 | ) | (14,663 | ) | |||
| Prepaid expenses, net deferred income taxes and other current assets | (69,988 | ) | 2,312 | ||||
| Accounts payable, accrued expenses, income taxes payable and other | 62,761 | 7,636 | |||||
| Net cash provided by (used in) operating activities | $ | 422,422 | $ | 457,321 | |||
| Cash flows from investing activities: | |||||||
| Purchases of property, plant, and equipment | (48,740 | ) | (42,965 | ) | |||
| Patent registration and acquisition costs | (2,432 | ) | (2,814 | ) | |||
| Business acquisitions, net of cash acquired | (7,487 | ) | (522 | ) | |||
| Purchases of investments | (2,721 | ) | (2,173 | ) | |||
| Proceeds from divestment of subsidiaries, net of cash divested | 450,820 | — | |||||
| Proceeds (payments) on maturity of foreign currency contracts | 2,615 | (4,104 | ) | ||||
| Net cash provided by (used in) investing activities | $ | 392,055 | $ | (52,578 | ) | ||
| Cash flows from financing activities: | |||||||
| Proceeds from issuance of common stock, net | 3,654 | 8,205 | |||||
| Purchases of treasury stock | (936,378 | ) | (150,010 | ) | |||
| Taxes paid related to net share settlement of equity awards | (325 | ) | (719 | ) | |||
| Repayment of borrowings | (250,000 | ) | — | ||||
| Dividends paid | (94,954 | ) | (87,750 | ) | |||
| Net cash provided by (used in) financing activities | $ | (1,278,003 | ) | $ | (230,274 | ) | |
| Effect of exchange rate changes on cash | $ | 5,034 | $ | (71 | ) | ||
| Net increase (decrease) in cash and cash equivalents | (458,492 | ) | 174,398 | ||||
| Cash and cash equivalents at beginning of period | 1,469,234 | 1,209,450 | |||||
| Cash and cash equivalents at end of period | $ | 1,010,742 | $ | 1,383,848 |
– More –
**RESMED INC. AND SUBSIDIARIES
**
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in millions, except for per share amounts)
In addition to financial information prepared in accordance with GAAP, we use certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.
The non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide our detailed reconciliations to the corresponding GAAP financial measures) are adjusted for the impact of acquisitions and divestitures, amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment-related expenses, gains on divestment of subsidiaries, and associated tax effects, in addition to the tax effect of interest and penalties on tax refunds.
We have not included a reconciliation of forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.
Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):
Scroll to view ↔
| Three Months Ended | |||||
| September 30, 2026 | September 30, 2025 | ||||
| GAAP total revenue growth | 6 | % | 9 | % | |
| Impact of: | |||||
| Acquisitions/divestitures (A) | 1 | — | |||
| Effect of foreign currency fluctuations (A) | — | (1 | ) | ||
| Non-GAAP core constant currency total revenue growth | 7 | % | 8 | % |
- In order to provide a framework for assessing how our underlying businesses performed excluding the impact of the Noctrix acquisition and the divestiture of the MatrixCare business and the effect of foreign currency fluctuations, when applicable, we provide certain financial information on a “core constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
**RESMED INC. AND SUBSIDIARIES
**
**Reconciliation of Non-GAAP Financial Measures
**(Unaudited; $ in millions, except for per share amounts)
Scroll to view ↔
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||
| Gross profit | Research and development expenses | Selling, general, and administrative expenses | Income from operations | Total other income (loss), net | Income tax expense | Net income | Diluted earnings per share | |||||||||||||||||
| GAAP | $ | 871 | $ | 103 | $ | 315 | $ | 453 | $ | 86 | $ | 121 | $ | 418 | $ | 2.92 | ||||||||
| Amortization of acquired intangibles | 5 | — | (8 | ) | 14 | — | 4 | 10 | 0.07 | |||||||||||||||
| Restructuring and business transformation expenses | 8 | (1 | ) | (20 | ) | 29 | — | 7 | 22 | 0.16 | ||||||||||||||
| Acquisition and divestment related expenses | — | — | (10 | ) | 10 | — | — | 10 | 0.07 | |||||||||||||||
| Gain on divestment of subsidiary | — | — | — | — | (62 | ) | (7 | ) | (55 | ) | (0.38 | ) | ||||||||||||
| Income tax effect of interest income on tax refunds | — | — | — | — | — | (12 | ) | 12 | 0.07 | |||||||||||||||
| Non-GAAP (A) | $ | 884 | $ | 102 | $ | 276 | $ | 506 | $ | 24 | $ | 113 | $ | 418 | $ | 2.91 |
- Totals may not add due to rounding.
Scroll to view ↔
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||
| Gross profit | Research and development expenses | Selling, general, and administrative expenses | Income from operations | Total other income (loss), net | Income tax expense | Net income | Diluted earnings per share | |||||||||||||||||
| GAAP | $ | 818 | $ | 89 | $ | 282 | $ | 447 | $ | — | $ | 98 | $ | 349 | $ | 2.37 | ||||||||
| Amortization of acquired intangibles | 8 | — | (12 | ) | 20 | — | 5 | 15 | 0.10 | |||||||||||||||
| Restructuring and business transformation expenses | 3 | (2 | ) | (10 | ) | 16 | — | 4 | 12 | 0.08 | ||||||||||||||
| Non-GAAP (A) | $ | 829 | $ | 87 | $ | 259 | $ | 482 | $ | — | $ | 108 | $ | 375 | $ | 2.55 |
- Totals may not add due to rounding.
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
(Unaudited; $ in millions)
Scroll to view ↔
| Three Months Ended | |||||||||||
| September 30, 2026 | (A) | September 30, 2025 | (A) | % Change | Core Constant Currency (B) | ||||||
| Americas | |||||||||||
| Sleep Devices | $ | 436 | $ | 405 | 8 | % | 6 | % | |||
| Masks and other | 397 | 361 | 10 | 10 | |||||||
| Total Sleep | $ | 833 | $ | 766 | 9 | 8 | |||||
| Life Support Devices | — | 9 | (94 | ) | (94 | ) | |||||
| Total Americas Sleep and Breathing Health | $ | 833 | $ | 775 | 8 | 7 | |||||
| Rest of World | |||||||||||
| Sleep Devices | $ | 280 | $ | 250 | 12 | % | 13 | % | |||
| Masks and other | 143 | 128 | 12 | 11 | |||||||
| Total Sleep | $ | 423 | $ | 378 | 12 | 12 | |||||
| Life Support Devices | 3 | 17 | (79 | ) | (79 | ) | |||||
| Total Rest of World Sleep and Breathing Health | $ | 426 | $ | 395 | 8 | 8 | |||||
| Global revenue | |||||||||||
| Total Sleep Devices | $ | 716 | $ | 655 | 9 | % | 9 | % | |||
| Total Masks and other | 540 | 489 | 10 | 10 | |||||||
| Total Sleep | $ | 1,256 | $ | 1,144 | 10 | 9 | |||||
| Total Life Support Devices | 4 | 25 | (84 | ) | (84 | ) | |||||
| Total Sleep and Breathing Health | $ | 1,260 | $ | 1,169 | 8 | 7 | |||||
| Residential Care Software | 155 | 166 | (7 | ) | 5 | ||||||
| Total | $ | 1,415 | $ | 1,336 | 6 | % | 7 | % | |||
- Totals and subtotals may not add due to rounding.
- In order to provide a framework for assessing how our underlying businesses performed excluding the impact of the Noctrix acquisition and the divestiture of the MatrixCare business and the effect of foreign currency fluctuations, we provide certain financial information on a “core constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Removing the MatrixCare business that we’ve now divested, the remaining businesses of Residential Care Software – Brightree and MEDIFOX DAN - increased by 8%.
RESMED INC. AND SUBSIDIARIES
Reclassification of Prior-period Amounts
(Unaudited; $ in thousands)
During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. In connection with this change, we renamed "restructuring expenses" as "restructuring and business transformation expenses" to reflect the broader nature of the costs included within this category. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses.
Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows. The following table reconciles previously reported amounts to the revised presentation (in thousands):
Scroll to view ↔
| Three Months Ended September 30, 2025 | |||||||||||||||
| As previously reported | Restructuring and business transformation expenses | Amortization of acquired intangibles | As reclassified | ||||||||||||
| Cost of sales - Sleep and Breathing Health products | $ | 456,118 | $ | 3,156 | $ | 1,420 | $ | 460,694 | |||||||
| Cost of sales - Residential Care Software | 50,823 | — | 6,401 | 57,224 | |||||||||||
| Cost of sales (exclusive of amortization shown separately below) | $ | 506,941 | $ | 3,156 | $ | 7,821 | $ | 517,918 | |||||||
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 1,420 | — | (1,420 | ) | — | ||||||||||
| Amortization of acquired intangible assets - Residential Care Software | 6,401 | — | (6,401 | ) | — | ||||||||||
| Amortization of acquired intangible assets | $ | 7,821 | $ | — | $ | (7,821 | ) | $ | — | ||||||
| Total cost of sales | $ | 514,762 | $ | 3,156 | $ | — | $ | 517,918 | |||||||
| Gross profit | $ | 820,820 | $ | (3,156 | ) | $ | — | $ | 817,664 | ||||||
| Research and development | 87,323 | 2,156 | — | 89,479 | |||||||||||
| Selling, general, and administrative | 259,194 | 10,498 | 11,956 | 281,648 | |||||||||||
| Amortization of acquired intangible assets | 11,956 | — | (11,956 | ) | — | ||||||||||
| Restructuring expenses | 15,810 | (15,810 | ) | — | — | ||||||||||
| Total operating expenses | $ | 374,283 | $ | (3,156 | ) | $ | — | $ | 371,127 | ||||||
| Income from operations | $ | 446,537 | $ | — | $ | — | $ | 446,537 | |||||||
**
RESMED INC. AND SUBSIDIARIES**
Reclassification of Prior-period Amounts
(Unaudited; $ in thousands)
The following tables reconcile previously reported quarterly 2026 amounts to the revised presentation (in thousands):
Scroll to view ↔
| Three Months Ended December 31, 2025 | |||||||||||||||
| As previously reported | Restructuring and business transformation expenses | Amortization of acquired intangibles | As reclassified | ||||||||||||
| Cost of sales - Sleep and Breathing Health products | $ | 484,792 | $ | 994 | $ | 1,415 | $ | 487,201 | |||||||
| Cost of sales - Residential Care Software | 51,484 | — | 6,393 | 57,877 | |||||||||||
| Cost of sales (exclusive of amortization shown separately below) | $ | 536,276 | $ | 994 | $ | 7,808 | $ | 545,078 | |||||||
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 1,415 | — | (1,415 | ) | — | ||||||||||
| Amortization of acquired intangible assets - Residential Care Software | 6,393 | — | (6,393 | ) | — | ||||||||||
| Amortization of acquired intangible assets | $ | 7,808 | $ | — | $ | (7,808 | ) | $ | — | ||||||
| Total cost of sales | $ | 544,084 | $ | 994 | $ | — | $ | 545,078 | |||||||
| Gross profit | $ | 878,724 | $ | (994 | ) | $ | — | $ | 877,730 | ||||||
| Research and development | 90,969 | 1,233 | — | 92,202 | |||||||||||
| Selling, general, and administrative | 278,396 | 3,708 | 11,764 | 293,868 | |||||||||||
| Amortization of acquired intangible assets | 11,764 | — | (11,764 | ) | — | ||||||||||
| Restructuring expenses | 5,935 | (5,935 | ) | — | — | ||||||||||
| Total operating expenses | $ | 387,064 | $ | (994 | ) | $ | — | $ | 386,070 | ||||||
| Income from operations | $ | 491,660 | $ | — | $ | — | $ | 491,660 | |||||||
**
RESMED INC. AND SUBSIDIARIES
**
Reclassification of Prior-period Amounts
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended March 31, 2026 | |||||||||||||||
| As previously reported | Restructuring and business transformation expenses | Amortization of acquired intangibles | As reclassified | ||||||||||||
| Cost of sales - Sleep and Breathing Health products | $ | 481,722 | $ | — | $ | 1,421 | $ | 483,143 | |||||||
| Cost of sales - Residential Care Software | 50,855 | — | 6,429 | 57,284 | |||||||||||
| Cost of sales (exclusive of amortization shown separately below) | $ | 532,577 | $ | — | $ | 7,850 | $ | 540,427 | |||||||
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 1,421 | — | (1,421 | ) | — | ||||||||||
| Amortization of acquired intangible assets - Residential Care Software | 6,429 | — | (6,429 | ) | — | ||||||||||
| Amortization of acquired intangible assets | $ | 7,850 | $ | — | $ | (7,850 | ) | $ | — | ||||||
| Total cost of sales | $ | 540,427 | $ | — | $ | — | $ | 540,427 | |||||||
| Gross profit | $ | 890,979 | $ | — | $ | — | $ | 890,979 | |||||||
| Research and development | 94,267 | — | — | 94,267 | |||||||||||
| Selling, general, and administrative | 285,655 | — | 11,247 | 296,902 | |||||||||||
| Amortization of acquired intangible assets | 11,247 | — | (11,247 | ) | — | ||||||||||
| Restructuring expenses | — | — | — | — | |||||||||||
| Total operating expenses | $ | 391,169 | $ | — | $ | — | $ | 391,169 | |||||||
| Income from operations | $ | 499,810 | $ | — | $ | — | $ | 499,810 | |||||||
**
RESMED INC. AND SUBSIDIARIES
**
Reclassification of Prior-period Amounts
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended June 30, 2026 | |||||||||||||||
| As previously reported | Restructuring and business transformation expenses | Amortization of acquired intangibles | As reclassified | ||||||||||||
| Cost of sales - Sleep and Breathing Health products | $ | 539,975 | $ | — | $ | 2,011 | $ | 541,986 | |||||||
| Cost of sales - Residential Care Software | 54,155 | — | 6,290 | 60,445 | |||||||||||
| Cost of sales (exclusive of amortization shown separately below) | $ | 594,130 | $ | — | $ | 8,301 | $ | 602,431 | |||||||
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 2,011 | — | (2,011 | ) | — | ||||||||||
| Amortization of acquired intangible assets - Residential Care Software | 6,290 | — | (6,290 | ) | — | ||||||||||
| Amortization of acquired intangible assets | $ | 8,301 | $ | — | $ | (8,301 | ) | $ | — | ||||||
| Total cost of sales | $ | 602,431 | $ | — | $ | — | $ | 602,431 | |||||||
| Gross profit | $ | 861,216 | $ | — | $ | — | $ | 861,216 | |||||||
| Research and development | 105,726 | — | — | 105,726 | |||||||||||
| Selling, general, and administrative | 296,283 | — | 10,499 | 306,782 | |||||||||||
| Amortization of acquired intangible assets | 10,499 | — | (10,499 | ) | — | ||||||||||
| Restructuring expenses | — | — | — | — | |||||||||||
| Total operating expenses | $ | 412,508 | $ | — | $ | — | $ | 412,508 | |||||||
| Income from operations | $ | 448,708 | $ | — | $ | — | $ | 448,708 |
Scroll to view ↔
| For investors | For media |
| +1 858-221-3304 | +1 619-510-1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released October 29, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
October 19, 2026 8:00am EDT
Latest addition to Resmed’s growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for people with obstructive sleep apnea (OSA) to provide greater comfort and choice in therapy1, the AirTouch F40 helps address key factors that can influence long-term adherence.
OSA is a growing health challenge, affecting more than one billion people worldwide.2 In the U.S., an estimated 61 million people have OSA, a number projected to rise to nearly 77 million by 2050.3 CPAP therapy remains the gold standard treatment for OSA4, and for those on CPAP, mask comfort and fit can play an important role in how people stay engaged with therapy over time.
AirTouch F40 brings Resmed’s proprietary ComfiSoft™ fabric cushion to a minimalist design that is intended to adapt to a person’s face as they move throughout the night. Because comfort preferences vary from person to person, expanding mask choice helps give people another option to meet their individual needs. The mask’s wide fit range and intuitive design are also intended to make it easier for healthcare providers to help patients find a comfortable fit and support them throughout therapy.
AirTouch F40 builds on Resmed’s growing portfolio of fabric-based mask technology and reflects the company’s commitment to delivering more personalized experiences that support patients throughout their therapy experience. Resmed has seen encouraging outcomes across its fabric mask portfolio, including a 6% increase in 90-day compliance among users of a fabric-cushioned mask compared with users of a silicone-cushioned mask.5
“AirTouch F40 is one example of how we're continuing to redefine what's possible to create more comfortable and personalized therapy experiences,” said Justin Leong, Chief Product Officer at Resmed. “By building on the success of AirFit F40™ and introducing a new fabric option, we're giving people greater flexibility to choose the mask that works best for them. That's the kind of innovation that can help more people start and stay on CPAP therapy.”
Key features of AirTouch F40 include:
- Designed to fit and move with the user: AirTouch F40 is designed to fit 96% of people6 with a minimalist design that adapts to the face as people move throughout the night.
- Brings fabric comfort to the full-face experience: The ComfiSoft fabric cushion features soft, breathable, and moisture-wicking fabric7 designed for comfort against the skin.
- A familiar platform for existing AirFit F40 users: The interchangeable cushion allows current AirFit F40 users to try the fabric cushion without changing mask systems or being resized or refitted.
Connected support throughout therapy
AirTouch F40 is part of Resmed’s connected sleep health platform, bringing together devices, digital tools and provider support to create a more connected therapy experience and help people stay engaged over time.
Through myAir™, Resmed’s patient engagement app, people can track their therapy progress, access personalized guidance and receive ongoing support throughout their therapy experience. This includes upcoming features such as Equipment Care, a tool that is designed to encourage patients to take action and stay engaged in managing their CPAP equipment. Healthcare providers can use AirView™, Resmed’s remote monitoring platform, to view therapy insights and support patients between appointments. When used alongside AirView, myAir has been shown to improve therapy compliance from 70% to 87%.8
AirTouch F40 will be available in the U.S. beginning October 28, 2026. For more information, visit https://www.resmed.com/en-us/health-professionals/campaigns/airtouch-f40/
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.
For Media
Keleigh Andrus
[email protected]
For Investors
Salli Schwartz
[email protected]
1 Resmed external crossover study comparing AirTouch F40 mask against other Resmed and third-party masks. n=36. Data on file, ID: A5768170.
2 Benjafield AV, et al. Lancet Respir Med. 2019 Aug; 7(8):687-698.
3 Boers E, et al. Lancet Respir Med. 2025;13(12):1078–1086.
4 Patil SP et al. J Clin Sleep Med. 2019 Feb 15;15(2):301-334.
5 Resmed analysis of 90-day PAP compliance among U.S. patients using AirView™ and myAir™, comparing AirTouch™ N30i and AirFit™ N30i. Data on file, ID: A5707362.
6 Internal Resmed analysis of projected cushion fit per region. Data on file, ID: A5756043.
7 Resmed internal testing of the moisture-wicking properties of fabric. Data on file, ID: A5636924.
8 Malhotra et al., CHEST. 2018; 153(4): 843–850.
Source: Resmed, Inc.
Released October 19, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
October 01, 2026 4:05pm EDT
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
-
Location: https://investor.resmed.com
-
Date: Thursday, October 29, 2026
-
Time: 1:30 p.m. PT / 4:30 p.m. ET
-
International: London, Thursday, October 29, 2026, 8:30 p.m. GMT
Sydney, Friday, October 30, 2026, 7:30 a.m. AEDT
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from October 29, 2026, until November 12, 2026, at:
- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13762822
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For investors | For media | |
| +1 858.221.3304 | +1 619.510.1281 | |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released October 1, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
On August 31, 2026, ResMed Inc. (the “Company”) entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Citibank, N.A. (“Citibank”) to repurchase $450.0 million of the Company’s shares of common stock, par value $0.004 per share (“Common Stock”). The Company is conducting the accelerated share repurchase under a repurchase authorization for an aggregate of 20,000,000 shares of Common Stock approved by its board of directors in February 2014. The Company intends to fund the accelerated share repurchase with the proceeds from the sale of its MatrixCare business and cash on hand. This ASR transaction was contemplated in the guidance we issued for fiscal year 2027 during our Q4 FY26 earnings call on August 6, 2026. Pursuant to the ASR Agreement, the Company will make a payment of $450.0 million to Citibank on September 3, 2026 and expects to receive on the same day an initial delivery from Citibank of a number of shares of Common Stock equal to 80% of $450.0 million divided by the closing price of the Common Stock on September 2, 2026.
August 27, 2026 4:05pm EDT
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed’s webcast presentation will begin at approximately 10:00 a.m. (Eastern Time).
More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com . The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For investors | For media |
| +1 858.221.3304 | +1 619.510.1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released August 27, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
August 25, 2026 9:00am EDT
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine
SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced a new collaboration with 23XI Racing and their NASCAR Cup Series driver Tyler Reddick to encourage more people to recognize the signs of sleep apnea and seek diagnosis and treatment.
In NASCAR, sustained concentration, physical endurance and split-second decisions can be the difference between winning and losing. Research shows that even one night of poor sleep can impair sustained attention and increase reaction time.1 After being diagnosed with obstructive sleep apnea (OSA) and starting continuous positive airway pressure (CPAP) therapy in early 2026, Tyler went on to become the first driver in NASCAR Cup Series history to open a season with three consecutive victories, which included the Daytona 500. His experience highlights the performance advantage that treating his sleep apnea can provide.
For years, Reddick dismissed his sleep apnea symptoms, including loud snoring, morning headaches, low energy and waking up feeling unrested. His experience reflects a broader challenge. OSA, the most common form of sleep apnea, impacts nearly 1 billion people globally2, yet more than 80% of cases remain undiagnosed and untreated3, often because symptoms are mistaken as normal. Reddick is sharing his experience to help raise awareness of sleep apnea and encourage people experiencing poor sleep to seek care sooner.
“Looking back, I had sleep apnea symptoms for a long time, but I didn’t think it was something that could affect me,” said Reddick. “I noticed a difference after night one of using my Resmed CPAP therapy, and it completely changed the way I approach recovery, preparation and performance. I've realized that a competitive edge is built through the habits you commit to every day, and prioritizing my sleep health has become one of the most important. If sharing my experience helps someone else recognize the signs and take action, that's a win.”
OSA can affect anyone, including people who appear healthy and active. Left untreated, it is associated with serious health conditions including cardiovascular disease, stroke and diabetes.4,5 CPAP therapy, the gold standard treatment for OSA, works by delivering pressurized air through a mask to help keep the airway open during sleep.6
“Tyler's willingness to share his story helps challenge outdated assumptions about who can have sleep apnea,” said Carlos Nunez, MD, chief medical officer at Resmed. “Sleep apnea affects people of all ages, body types and health profiles, yet many people may not realize their daytime fatigue could be connected to how they breathe at night. By amplifying Tyler’s journey, we hope more people recognize the signs, seek care and experience the life-changing benefits CPAP treatment can have on their health.”
Throughout the remainder of the 2026 NASCAR season, Resmed and Reddick will share sleep health education through Tyler's personal journey with sleep apnea, encouraging more people to recognize the signs and understand the role sleep plays in recovery and performance. Resmed branding will also be present on track with 23XI on Reddick’s No. 45 Toyota Camry XSE at select NASCAR Cup Series races:
- Bristol Motor Speedway, Sept. 19
- Talladega Superspeedway, Oct. 25
- Homestead-Miami Speedway, Nov. 8
Think you may have sleep apnea? Take Resmed's Sleep Assessment to learn more about your sleep and next steps.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.
About 23XI Racing
23XI Racing – pronounced twenty-three eleven – was founded by NBA legend Michael Jordan and three-time Daytona 500 winner Denny Hamlin in 2020. With rising NASCAR star Bubba Wallace selected to drive the No. 23 Toyota Camry, the team made its NASCAR Cup Series debut in the 2021 Daytona 500 at Daytona International Speedway. Wallace made history on October 4, 2021, when he captured his first career Cup Series win, becoming just the second African American to win in the Cup Series, and earning 23XI its first-ever victory. 23XI expanded to a two-car organization in 2022 with Cup Series Champion and Hall of Famer Kurt Busch driving the No. 45 Toyota Camry. With a win at Kansas Speedway in May of 2022, Busch earned 23XI the team’s first-ever playoff berth. Tyler Reddick joined the team in 2023 to drive the No. 45 car. In 2024, Reddick won the Regular Season Championship and raced to a spot in the Championship 4, a first for both the team and Reddick. In 2026, Reddick made history by winning the first three Cup Series races of the season, including the Daytona 500. 23XI currently features the lineup of Bubba Wallace in the No. 23 Toyota Camry XSE, Tyler Reddick in the No. 45 Toyota Camry XSE and Riley Herbst in the No. 35 Toyota Camry XSE. Corey Heim currently serves as the team’s development driver and races occasionally in the No. 67 Toyota Camry XSE. The team operates out of Airspeed, a state-of-the-art facility in Huntersville, N.C.
Resmed
For Media
Caela Shay
[email protected]
For Investors
Salli Schwartz
[email protected]
23XI
For Media
Davis Shaefer
[email protected]
1 Wüst LN, Capdevila N, Lane LT, et al. Impact of one night of sleep restriction on sleepiness and cognitive function: A systematic review and meta-analysis. Sleep Medicine Reviews. 2024;76:101940. doi:10.1016/j.smrv.2024.101940.
2 Benjafield et al., The Lancet Respiratory Medicine (2019), “Estimation of the global prevalence and burden of obstructive sleep apnoea”
3 Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice. Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017
4 Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers_._ 2015;1:15015. https://doi.org/10.1038/nrdp.2015.15
5 Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e56–e67. https://doi.org/10.1161/CIR.0000000000000988
6 Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335–343. https://doi.org/10.5664/jcsm.7640
Source: Resmed, Inc.
Released August 25, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
August 17, 2026 4:10pm EDT
- Nominating and Governance Chair Carol Burt to become Lead Director.
- Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelection at the company’s 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.
The Board has appointed Carol Burt to serve as Lead Director, effective November 15, 2026. Burt has served on Resmed’s Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee. Burt's extensive board leadership and governance experience position her well to serve as Lead Director as the company continues to execute its long-term strategy.
“Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to Resmed's mission,” said Mick Farrell, Resmed’s Chairman and CEO. “I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders.”
Ron Taylor joined Resmed’s Board of Directors in 2005 and has served in numerous leadership roles, including as Lead Director since 2013. During his tenure, Ron helped guide the company's governance, strategy and long-term growth while providing thoughtful leadership and independent oversight during a period of significant growth and transformation.
“Ron has made extraordinary contributions to Resmed over the past two decades,” said Farrell. “His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape Resmed. On behalf of the Board and all Resmedians, I thank Ron for his outstanding service and wish him and his family all the very best.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com
and follow @Resmed.
For Media
Brad Lotterman
[email protected]
For Investors
Salli Schwartz
[email protected]
Source: Resmed, Inc.
Released August 17, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
August 06, 2026 4:05pm EDT
Related Documents
Earnings WebcastAudio Transcript
- Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis
- Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95
- Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70%
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.
“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.
“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”
“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.”
Financial Highlights
- FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis
- FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%
- FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%
- FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an increase of 17%
- FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion
- Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter
Other Business and Operational Highlights
- Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027.
- Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable therapeutics for Restless Leg Syndrome, or RLS.
- Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
- Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
Scroll to view ↔
| Three Months Ended | |||||||||||||
| June 30, 2026 | June 30, 2025 | % Change | Constant Currency_(A)_ | ||||||||||
| Revenue | $ | 1,464 | $ | 1,348 | 9 | % | 8 | % | |||||
| Gross margin | 58.8 | % | 60.8 | % | (200) bps | ||||||||
| Non-GAAP gross margin_(B)_ | 62.3 | % | 61.4 | % | 90 bps | ||||||||
| Research and development expenses | 106 | 86 | 22 | 19 | |||||||||
| Selling, general, and administrative expenses | 296 | 267 | 11 | 8 | |||||||||
| Non-GAAP selling, general, and administrative expenses_(B)_ | 291 | 265 | 10 | 7 | |||||||||
| Income from operations | 449 | 455 | (1 | ) | |||||||||
| Operating margin | 30.7 | % | 33.7 | % | (300) bps | ||||||||
| Non-GAAP income from operations_(B)_ | 515 | 476 | 8 | ||||||||||
| Non-GAAP operating margin | 35.2 | % | 35.3 | % | (10) bps | ||||||||
| Net income | 383 | 380 | 1 | ||||||||||
| Non-GAAP net income_(B)_ | 428 | 375 | 14 | ||||||||||
| Diluted earnings per share | $ | 2.64 | $ | 2.58 | 2 | ||||||||
| Non-GAAP diluted earnings per share_(B)_ | $ | 2.95 | $ | 2.55 | 16 | ||||||||
| Operating cash flow | 455 | 539 | (16 | ) | |||||||||
| Free cash flow_(C)_ | 404 | 508 | (21 | ) |
Scroll to view ↔
| Twelve Months Ended | |||||||||||||
| June 30, 2026 | June 30, 2025 | % Change | Constant Currency_(A)_ | ||||||||||
| Revenue | $ | 5,653 | $ | 5,146 | 10 | % | 8 | % | |||||
| Gross margin | 61.1 | % | 59.4 | % | 170 bps | ||||||||
| Non-GAAP gross margin_(B)_ | 62.4 | % | 60.0 | % | 240 bps | ||||||||
| Research and development expenses | 378 | 331 | 14 | 12 | |||||||||
| Selling, general, and administrative expenses | 1,120 | 993 | 13 | 10 | |||||||||
| Non-GAAP selling, general, and administrative expenses_(B)_ | 1,108 | 991 | 12 | 9 | |||||||||
| Income from operations | 1,887 | 1,685 | 12 | ||||||||||
| Operating margin | 33.4 | % | 32.7 | % | 70 bps | ||||||||
| Non-GAAP income from operations_(B)_ | 2,039 | 1,763 | 16 | ||||||||||
| Non-GAAP operating margin | 36.1 | % | 34.3 | % | 180 bps | ||||||||
| Net income | 1,523 | 1,401 | 9 | ||||||||||
| Non-GAAP net income_(B)_ | 1,632 | 1,407 | 16 | ||||||||||
| Diluted earnings per share | $ | 10.43 | $ | 9.51 | 10 | ||||||||
| Non-GAAP diluted earnings per share_(B)_ | $ | 11.17 | $ | 9.55 | 17 | ||||||||
| Operating cash flow | 1,806 | 1,752 | 3 | ||||||||||
| Free cash flow_(C)_ | 1,650 | 1,662 | (1 | ) |
(A) In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
(C) Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.
Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted
-
Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion, driven by strong demand across sleep devices, masks, accessories, and software solutions.
-
Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and Breathing Health grew 10% in constant currency, and Residential Care Software revenue increased 2% in constant currency.
-
Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross margin increased 90 basis points to 62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral field safety notification expenses.
-
Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per share of $2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per share grew 16% to $2.95, predominantly attributable to strong sales growth and gross margin improvement.
-
Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled $404 million, supporting $287 million returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.
Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive.
Webcast details
Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13761408. The telephone replay will be available until August 20, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | |||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||
| Net revenue | $ | 1,463,647 | $ | 1,347,993 | $ | 5,653,443 | $ | 5,146,327 | ||||||
| Cost of sales | 552,245 | 520,068 | 2,128,040 | 2,060,753 | ||||||||||
| Amortization of acquired intangibles_(1)_ | 8,301 | 9,367 | 31,779 | 32,116 | ||||||||||
| Masks with magnets field safety notification expenses_(1)_ | — | (1,512 | ) | — | (1,512 | ) | ||||||||
| Astral field safety notification expenses_(1)_ | 41,885 | — | 41,885 | — | ||||||||||
| Total cost of sales | $ | 602,431 | $ | 527,923 | $ | 2,201,704 | $ | 2,091,357 | ||||||
| Gross profit | $ | 861,216 | $ | 820,070 | $ | 3,451,739 | $ | 3,054,970 | ||||||
| Research and development | 105,726 | 86,443 | 378,285 | 331,284 | ||||||||||
| Selling, general, and administrative | 290,655 | 265,125 | 1,108,042 | 991,019 | ||||||||||
| Acquisition and portfolio review related expenses_(1)_ | 5,628 | 2,031 | 11,486 | 2,031 | ||||||||||
| Total selling, general, and administrative | 296,283 | 267,156 | 1,119,528 | 993,050 | ||||||||||
| Amortization of acquired intangibles_(1)_ | 10,499 | 11,928 | 45,466 | 45,273 | ||||||||||
| Restructuring expenses_(1)_ | — | — | 21,745 | — | ||||||||||
| Total operating expenses | $ | 412,508 | $ | 365,527 | $ | 1,565,024 | $ | 1,369,607 | ||||||
| Income from operations | $ | 448,708 | $ | 454,543 | $ | 1,886,715 | $ | 1,685,363 | ||||||
| Other income (expenses), net: | ||||||||||||||
| Interest (expense) income, net | $ | 20,885 | $ | 5,757 | $ | 49,914 | $ | 4,114 | ||||||
| Gain (loss) attributable to equity method investments | 2,232 | 1,269 | 6,955 | 3,644 | ||||||||||
| Gain (loss) on equity investments | 1,001 | (2,533 | ) | (15,014 | ) | (10,299 | ) | |||||||
| Other, net | 1,338 | (983 | ) | (9,154 | ) | (5,256 | ) | |||||||
| Total other income (expenses), net | 25,456 | 3,510 | 32,701 | (7,797 | ) | |||||||||
| Income before income taxes | $ | 474,164 | $ | 458,053 | $ | 1,919,416 | $ | 1,677,566 | ||||||
| Income taxes | 90,732 | 78,348 | 396,123 | 276,843 | ||||||||||
| Net income | $ | 383,432 | $ | 379,705 | $ | 1,523,293 | $ | 1,400,723 | ||||||
| Basic earnings per share | $ | 2.65 | $ | 2.59 | $ | 10.47 | $ | 9.55 | ||||||
| Diluted earnings per share | $ | 2.64 | $ | 2.58 | $ | 10.43 | $ | 9.51 | ||||||
| Non-GAAP diluted earnings per share_(1)_ | $ | 2.95 | $ | 2.55 | $ | 11.17 | $ | 9.55 | ||||||
| Basic shares outstanding | 144,706 | 146,472 | 145,523 | 146,716 | ||||||||||
| Diluted shares outstanding | 144,976 | 147,037 | 146,054 | 147,340 |
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
Scroll to view ↔
| June 30, 2026 | June 30, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,469,234 | $ | 1,209,450 | |||
| Accounts receivable, net | 1,036,233 | 939,492 | |||||
| Inventories | 945,805 | 927,711 | |||||
| Prepayments and other current assets | 416,081 | 428,952 | |||||
| Assets held for sale | $ | 457,386 | $ | — | |||
| Total current assets | $ | 4,324,739 | $ | 3,505,605 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 581,829 | $ | 550,790 | |||
| Operating lease right-of-use assets | 153,167 | 167,497 | |||||
| Goodwill and other intangibles, net | 3,362,312 | 3,511,541 | |||||
| Deferred income taxes and other non-current assets | 543,903 | 438,958 | |||||
| Total non-current assets | $ | 4,641,211 | $ | 4,668,786 | |||
| Total assets | $ | 8,965,950 | $ | 8,174,391 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 308,923 | $ | 278,157 | |||
| Accrued expenses | 494,921 | 402,253 | |||||
| Operating lease liabilities, current | 29,141 | 30,506 | |||||
| Deferred revenue | 162,911 | 166,030 | |||||
| Income taxes payable | 98,108 | 132,274 | |||||
| Short-term debt | 259,950 | 9,900 | |||||
| Liabilities held for sale | $ | 41,156 | $ | — | |||
| Total current liabilities | $ | 1,395,110 | $ | 1,019,120 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 170,951 | $ | 156,803 | |||
| Deferred income taxes | 64,640 | 77,682 | |||||
| Operating lease liabilities, non-current | 137,413 | 153,015 | |||||
| Other long-term liabilities | 213,028 | 141,520 | |||||
| Long-term debt | 399,415 | 658,392 | |||||
| Total non-current liabilities | $ | 985,447 | $ | 1,187,412 | |||
| Total liabilities | $ | 2,380,557 | $ | 2,206,532 | |||
| Stockholders’ equity | |||||||
| Common stock | $ | 764 | $ | 761 | |||
| Additional paid-in capital | 2,190,614 | 2,033,599 | |||||
| Retained earnings | 7,255,121 | 6,081,490 | |||||
| Treasury stock | (2,778,591 | ) | (2,073,292 | ) | |||
| Accumulated other comprehensive income | (82,515 | ) | (74,699 | ) | |||
| Total stockholders’ equity | $ | 6,585,393 | $ | 5,967,859 | |||
| Total liabilities and stockholders’ equity | $ | 8,965,950 | $ | 8,174,391 |
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 383,432 | $ | 379,705 | $ | 1,523,293 | $ | 1,400,723 | |||||||
| Adjustment to reconcile net income to cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 44,778 | 63,628 | 201,342 | 198,473 | |||||||||||
| Amortization of right-of-use assets | 10,343 | 10,660 | 42,810 | 37,338 | |||||||||||
| Stock-based compensation costs | 27,458 | 24,751 | 104,348 | 91,661 | |||||||||||
| (Gain) loss attributable to equity method investments, net of dividends received | 2,340 | (1,269 | ) | (2,382 | ) | (3,644 | ) | ||||||||
| (Gain) loss on equity investments | (1,000 | ) | 2,533 | 15,014 | 10,299 | ||||||||||
| Gain on previously held equity investment | (4,353 | ) | — | (4,353 | ) | — | |||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable, net | (37,209 | ) | (5,215 | ) | (96,778 | ) | (76,684 | ) | |||||||
| Inventories, net | (33,866 | ) | (32,133 | ) | (9,920 | ) | (80,165 | ) | |||||||
| Prepaid expenses, net deferred income taxes and other current assets | 12,150 | 47,017 | (140,260 | ) | 82,629 | ||||||||||
| Accounts payable, accrued expenses, income taxes payable and other | 50,558 | 49,089 | 172,715 | 90,958 | |||||||||||
| Net cash provided by (used in) operating activities | $ | 454,631 | $ | 538,766 | $ | 1,805,829 | $ | 1,751,588 | |||||||
| Cash flows from investing activities: | |||||||||||||||
| Purchases of property, plant, and equipment | (51,127 | ) | (30,585 | ) | (156,285 | ) | (89,865 | ) | |||||||
| Patent registration and acquisition costs | (5,384 | ) | (3,193 | ) | (18,670 | ) | (10,777 | ) | |||||||
| Purchases of intangible assets | (739 | ) | — | (2,218 | ) | — | |||||||||
| Business acquisitions, net of cash acquired | (325,319 | ) | (138,578 | ) | (350,724 | ) | (139,248 | ) | |||||||
| Purchases of investments | (2,000 | ) | (2,013 | ) | (28,536 | ) | (6,416 | ) | |||||||
| Proceeds from exits of investments | — | 250 | 2,752 | 4,628 | |||||||||||
| Proceeds (payments) on maturity of foreign currency contracts | 918 | 40,406 | 8,482 | 41,633 | |||||||||||
| Net cash provided by (used in) investing activities | $ | (383,651 | ) | $ | (133,713 | ) | $ | (545,199 | ) | $ | (200,045 | ) | |||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from issuance of common stock, net | 29,314 | 30,156 | 74,503 | 74,439 | |||||||||||
| Purchases of treasury stock | (200,000 | ) | (100,008 | ) | (700,037 | ) | (300,025 | ) | |||||||
| Acquisition of consolidated subsidiary | — | (10,855 | ) | — | (10,855 | ) | |||||||||
| Taxes paid related to net share settlement of equity awards | (388 | ) | (590 | ) | (21,833 | ) | (18,077 | ) | |||||||
| Payments of business combination contingent consideration | — | — | — | (855 | ) | ||||||||||
| Repayment of borrowings | (5,000 | ) | (5,000 | ) | (10,000 | ) | (40,000 | ) | |||||||
| Dividends paid | (87,090 | ) | (77,590 | ) | (349,662 | ) | (310,880 | ) | |||||||
| Net cash provided by (used in) financing activities | $ | (263,164 | ) | $ | (163,887 | ) | $ | (1,007,029 | ) | $ | (606,253 | ) | |||
| Effect of exchange rate changes on cash | $ | 905 | $ | 35,573 | $ | 6,183 | $ | 25,799 | |||||||
| Net increase (decrease) in cash and cash equivalents | (191,279 | ) | 276,739 | 259,784 | 971,089 | ||||||||||
| Cash and cash equivalents at beginning of period | 1,660,513 | 932,711 | 1,209,450 | 238,361 | |||||||||||
| Cash and cash equivalents at end of period | $ | 1,469,234 | $ | 1,209,450 | $ | 1,469,234 | $ | 1,209,450 |
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below:
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||||
| Revenue | $ | 1,463,647 | $ | 1,347,993 | $ | 5,653,443 | $ | 5,146,327 | |||||||
| GAAP cost of sales | $ | 602,431 | $ | 527,923 | $ | 2,201,704 | $ | 2,091,357 | |||||||
| Less:Amortization of acquired intangibles(A) | (8,301 | ) | (9,367 | ) | (31,779 | ) | (32,116 | ) | |||||||
| Less: Masks with magnets field safety notification expenses_(A)_ | — | 1,512 | — | 1,512 | |||||||||||
| Less: Astral field safety notification expenses_(A)_ | (41,885 | ) | — | (41,885 | ) | — | |||||||||
| Non-GAAP cost of sales | $ | 552,245 | $ | 520,068 | $ | 2,128,040 | $ | 2,060,753 | |||||||
| GAAP gross profit | $ | 861,216 | $ | 820,070 | $ | 3,451,739 | $ | 3,054,970 | |||||||
| GAAP gross margin | 58.8 | % | 60.8 | % | 61.1 | % | 59.4 | % | |||||||
| Non-GAAP gross profit | $ | 911,402 | $ | 827,925 | $ | 3,525,403 | $ | 3,085,574 | |||||||
| Non-GAAP gross margin | 62.3 | % | 61.4 | % | 62.4 | % | 60.0 | % |
The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||||
| Revenue | $ | 1,463,647 | $ | 1,347,993 | $ | 5,653,443 | $ | 5,146,327 | |||||||
| GAAP selling, general, and administrative | 296,283 | 267,156 | 1,119,528 | 993,050 | |||||||||||
| Less:Acquisition and portfolio review related expenses(A) | (5,628 | ) | (2,031 | ) | (11,486 | ) | (2,031 | ) | |||||||
| Non-GAAP selling, general, and administrative | 290,655 | 265,125 | 1,108,042 | 991,019 | |||||||||||
| As a percentage of revenue: | |||||||||||||||
| GAAP selling, general, and administrative expenses | 20.2 | % | 19.8 | % | 19.8 | % | 19.3 | % | |||||||
| Non-GAAP selling, general, and administrative expenses | 19.9 | % | 19.7 | % | 19.6 | % | 19.3 | % |
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | ||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||
| GAAP income from operations | $ | 448,708 | $ | 454,543 | $ | 1,886,715 | $ | 1,685,363 | |||||
| Amortization of acquired intangibles—cost of sales_(A)_ | 8,301 | 9,367 | 31,779 | 32,116 | |||||||||
| Amortization of acquired intangibles—operating expenses_(A_) | 10,499 | 11,928 | 45,466 | 45,273 | |||||||||
| Restructuring_(A)_ | — | — | 21,745 | — | |||||||||
| Masks with magnets field safety notification expenses_(A)_ | — | (1,512 | ) | — | (1,512 | ) | |||||||
| Astral field safety notification expenses_(A)_ | 41,885 | — | 41,885 | — | |||||||||
| Acquisition and portfolio review related expenses_(A_) | 5,628 | 2,031 | 11,486 | 2,031 | |||||||||
| Non-GAAP income from operations | $ | 515,021 | $ | 476,357 | $ | 2,039,076 | $ | 1,763,271 |
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
Scroll to view ↔
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | ||||||||||||
| GAAP net income | $ | 383,432 | $ | 379,705 | $ | 1,523,293 | $ | 1,400,723 | |||||||
| Amortization of acquired intangibles—cost of sales_(A)_ | 8,301 | 9,367 | 31,779 | 32,116 | |||||||||||
| Amortization of acquired intangibles—operating expenses_(A)_ | 10,499 | 11,928 | 45,466 | 45,273 | |||||||||||
| Restructuring expenses_(A)_ | — | — | 21,745 | — | |||||||||||
| Gain on previously held equity investment(A) | (4,353 | ) | — | (4,353 | ) | — | |||||||||
| Masks with magnets field safety notification expenses_(A)_ | — | (1,512 | ) | — | (1,512 | ) | |||||||||
| Astral field safety notification expenses_(A)_ | 41,885 | — | 41,885 | — | |||||||||||
| Acquisition and portfolio review related expenses(A) | 5,628 | 2,031 | 11,486 | 2,031 | |||||||||||
| Tax benefit from business cessation(A) | — | (21,430 | ) | — | (21,430 | ) | |||||||||
| Income tax effect of interest and penalties on income tax refunds_(A)_ | — | — | — | (29,976 | ) | ||||||||||
| Income tax effect on non-GAAP adjustments_(A)_ | (17,059 | ) | (5,544 | ) | (39,453 | ) | (20,448 | ) | |||||||
| Non-GAAP net income_(A)_ | $ | 428,333 | $ | 374,545 | $ | 1,631,848 | $ | 1,406,777 | |||||||
| GAAP diluted shares outstanding | 144,976 | 147,037 | 146,054 | 147,340 | |||||||||||
| GAAP diluted earnings per share | $ | 2.64 | $ | 2.58 | $ | 10.43 | $ | 9.51 | |||||||
| Non-GAAP diluted earnings per share_(A)_ | $ | 2.95 | $ | 2.55 | $ | 11.17 | $ | 9.55 |
(A) Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on previously held equity investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in addition to tax benefits from business cessation, and the tax effect of interest and penalties on tax refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)
Scroll to view ↔
| Three Months Ended | |||||||||||
| June 30, 2026 | (A) | June 30, 2025 | (A) | % Change | Constant Currency_(B)_ | ||||||
| Americas**(C)** | |||||||||||
| Devices | $ | 459 | $ | 433 | 6 | % | |||||
| Masks and other | 394 | 359 | 10 | ||||||||
| Total Americas**(C)** | $ | 853 | $ | 792 | 8 | ||||||
| Rest of World**(C)** | |||||||||||
| Devices | $ | 291 | $ | 261 | 12 | % | 9 | % | |||
| Masks and other | 148 | 128 | 16 | 12 | |||||||
| Total Rest of World**(C)** | $ | 439 | $ | 389 | 13 | 10 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 750 | $ | 694 | 8 | % | 7 | % | |||
| Total Masks and other | 542 | 487 | 11 | 10 | |||||||
| Total Sleep and Breathing Health | $ | 1,292 | $ | 1,181 | 9 | 8 | |||||
| Residential Care Software | 172 | 167 | 3 | 2 | |||||||
| Total | $ | 1,464 | $ | 1,348 | 9 | 8 | |||||
Scroll to view ↔
| Twelve Months Ended | |||||||||||
| June 30, 2026 | (A) | June 30, 2025 | (A) | % Change | Constant Currency_(B)_ | ||||||
| Americas**(C)** | |||||||||||
| Devices | $ | 1,768 | $ | 1,654 | 7 | % | |||||
| Masks and other | 1,513 | 1,343 | 13 | ||||||||
| Total Americas**(C)** | $ | 3,281 | $ | 2,998 | 9 | ||||||
| Rest of World**(C)** | |||||||||||
| Devices | $ | 1,124 | $ | 1,011 | 11 | % | 6 | % | |||
| Masks and other | 572 | 497 | 15 | 9 | |||||||
| Total Rest of World**(C)** | $ | 1,697 | $ | 1,507 | 13 | 7 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 2,892 | $ | 2,665 | 9 | % | 7 | % | |||
| Total Masks and other | 2,085 | 1,840 | 13 | 12 | |||||||
| Total Sleep and Breathing Health | $ | 4,978 | $ | 4,505 | 10 | 9 | |||||
| Residential Care Software | 676 | 641 | 5 | 4 | |||||||
| Total | $ | 5,653 | $ | 5,146 | 10 | 8 |
(A) Totals and subtotals may not add due to rounding.
(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(C) Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin America” and “Combined Europe, Asia, and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin America) and Rest of World (formerly Combined Europe, Asia, and other markets). The methodology for attributing revenue to these geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.
Scroll to view ↔
| For investors | For media |
| +1 858-221-3304 | +1 619-510-1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released August 6, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
For investors ‘+1 858-221-3304 [email protected]
For media +1 619-510-1281 [email protected] ‘
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 •
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis
•
Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95
•
Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70%
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, August 6, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026. “We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell. “Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.” “As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.” Financial Highlights •
FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis
•
FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%
•
FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%
•
FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an increase of 17%
•
FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion
•
Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter
Other Business and Operational Highlights •
Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027.
•
Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable therapeutics for Restless Leg Syndrome, or RLS.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 2 of 10
•
Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
•
Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
Financial Results and Operating Metrics Unaudited; $ in millions, except for per share amounts
Revenue Gross margin
Three Months Ended June 30, June 30, 2026 2025 % Change $ 1,464 $ 1,348 9% 58.8 % 60.8 % (200) bps
Non-GAAP gross margin (B)
61.4 %
90 bps
296
86 267
22 11
19 8
291 449 30.7 % 515 35.2 % 383 428 2.64 $ 2.95 $
265 455 33.7 % 476 35.3 % 380 375 2.58 2.55
10 (1) (300) bps 8 (10) bps 1 14 2 16
7
Operating cash flow
455
539
(16)
Free cash flow(C)
404
508
(21)
Research and development expenses Selling, general, and administrative expenses Non-GAAP selling, general, and administrative expenses(B) Income from operations Operating margin Non-GAAP income from operations (B) Non-GAAP operating margin Net income Non-GAAP net income (B) Diluted earnings per share Non-GAAP diluted earnings per share (B)
Revenue Gross margin
62.3 % 106
Constant Currency (A) 8%
$ $
Twelve Months Ended June 30, June 30, 2026 2025 % Change $ 5,653 $ 5,146 10 % 61.1 % 59.4 % 170 bps
Non-GAAP gross margin (B)
60.0 %
240 bps
331 993
14 13
12 10
991 1,685 32.7 % 1,763 34.3 % 1,401 1,407 9.51 9.55
12 12 70 bps 16 180 bps 9 16 10 17
9
Operating cash flow
1,108 1,887 33.4 % 2,039 36.1 % 1,523 1,632 10.43 $ 11.17 $ 1,806
1,752
3
Free cash flow(C)
1,650
1,662
(1)
Research and development expenses Selling, general, and administrative expenses Non-GAAP selling, general, and administrative expenses(B) Income from operations Operating margin Non-GAAP income from operations (B) Non-GAAP operating margin Net income Non-GAAP net income (B) Diluted earnings per share Non-GAAP diluted earnings per share (B)
(A)
62.4 % 378
Constant Currency (A) 8%
1,120
$ $
In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 (B)
See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
(C)
Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.
Page 3 of 10
Discussion of Fourth Quarter Results All comparisons are to the prior year period unless otherwise noted
•
Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion, driven by strong demand across sleep devices, masks, accessories, and software solutions.
•
Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and Breathing Health grew 10% in constant currency, and Residential Care Software revenue increased 2% in constant currency.
•
Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross margin increased 90 basis points to 62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral field safety notification expenses.
•
Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per share of $2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per share grew 16% to $2.95, predominantly attributable to strong sales growth and gross margin improvement.
•
Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled $404 million, supporting $287 million returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.
Dividend program The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The exdividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive. Webcast details Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13761408. The telephone replay will be available until August 20, 2026. About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 4 of 10
Safe harbor statement Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements. – More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 5 of 10
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited; $ in thousands, except for per share amounts) Three Months Ended June 30, June 30, 2026 2025 Net revenue Cost of sales Amortization of acquired intangibles (1) Masks with magnets field safety notification expenses (1) Astral field safety notification expenses (1) Total cost of sales Gross profit
$
$ $
1,463,647
$
1,347,993
Twelve Months Ended June 30, June 30, 2026 2025 $
5,653,443
$
5,146,327
552,245 8,301
520,068 9,367
2,128,040 31,779
2,060,753 32,116
—
(1,512)
—
(1,512)
41,885 602,431 861,216
$ $
— 527,923 820,070
$ $
41,885 2,201,704 3,451,739
$ $
— 2,091,357 3,054,970
Research and development
105,726
86,443
378,285
331,284
Selling, general, and administrative Acquisition and portfolio review related expenses (1) Total selling, general, and administrative
290,655
265,125
1,108,042
991,019
5,628 296,283
2,031 267,156
11,486 1,119,528
2,031 993,050
Amortization of acquired intangibles (1) Restructuring expenses (1) Total operating expenses Income from operations
$ $
10,499 — 412,508 448,708
$ $
11,928 — 365,527 454,543
$ $
45,466 21,745 1,565,024 1,886,715
$ $
45,273 — 1,369,607 1,685,363
$
20,885
$
5,757
$
49,914
$
4,114
Other income (expenses), net: Interest (expense) income, net Gain (loss) attributable to equity method investments Gain (loss) on equity investments Other, net Total other income (expenses), net Income before income taxes Income taxes Net income Basic earnings per share Diluted earnings per share Non-GAAP diluted earnings per share (1) Basic shares outstanding Diluted shares outstanding
2,232
1,269
6,955
$
1,001 1,338 25,456 474,164 90,732 383,432
$
(2,533) (983) 3,510 458,053 $ 78,348 379,705 $
(15,014) (9,154) 32,701 1,919,416 $ 396,123 1,523,293 $
$ $ $
2.65 2.64 2.95
$ $ $
2.59 2.58 2.55
10.47 10.43 11.17
$
144,706 144,976
$
$ $ $
146,472 147,037
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
– More –
145,523 146,054
3,644
$ $ $
(10,299) (5,256) (7,797) 1,677,566 276,843 1,400,723 9.55 9.51 9.55 146,716 147,340
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 6 of 10
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited; $ in thousands) June 30, 2026
June 30, 2025
Assets Current assets: Cash and cash equivalents Accounts receivable, net Inventories Prepayments and other current assets Assets held for sale Total current assets Non-current assets: Property, plant, and equipment, net Operating lease right-of-use assets Goodwill and other intangibles, net Deferred income taxes and other non-current assets Total non-current assets Total assets
$
1,469,234 1,036,233 945,805 416,081
$
1,209,450 939,492 927,711 428,952
$ $
457,386 4,324,739
$ $
— 3,505,605
$
581,829 153,167 3,362,312 543,903 4,641,211 8,965,950
$
550,790 167,497 3,511,541 438,958 4,668,786 8,174,391
$
308,923 494,921 29,141 162,911 98,108 259,950
$
278,157 402,253 30,506 166,030 132,274 9,900
$ $
41,156 1,395,110
$ $
— 1,019,120
$
170,951 64,640 137,413 213,028 399,415 985,447 2,380,557
$
$ $
156,803 77,682 153,015 141,520 658,392 1,187,412 2,206,532
764 $ 2,190,614 7,255,121 (2,778,591) (82,515) 6,585,393 $ 8,965,950 $
761 2,033,599 6,081,490 (2,073,292) (74,699) 5,967,859 8,174,391
$ $
$ $
Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Accrued expenses Operating lease liabilities, current Deferred revenue Income taxes payable Short-term debt Liabilities held for sale Total current liabilities Non-current liabilities: Deferred revenue Deferred income taxes Operating lease liabilities, non-current Other long-term liabilities Long-term debt Total non-current liabilities Total liabilities
$ $
Stockholders’ equity Common stock Additional paid-in capital Retained earnings Treasury stock Accumulated other comprehensive income Total stockholders’ equity Total liabilities and stockholders’ equity
$
$ $
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 7 of 10
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited; $ in thousands) Three Months Ended June 30, June 30, 2026 2025 Cash flows from operating activities: Net income Adjustment to reconcile net income to cash provided by operating activities: Depreciation and amortization Amortization of right-of-use assets Stock-based compensation costs (Gain) loss attributable to equity method investments, net of dividends received (Gain) loss on equity investments
$
Gain on previously held equity investment Changes in operating assets and liabilities: Accounts receivable, net Inventories, net Prepaid expenses, net deferred income taxes and other current assets Accounts payable, accrued expenses, income taxes payable and other Net cash provided by (used in) operating activities Cash flows from investing activities: Purchases of property, plant, and equipment Patent registration and acquisition costs Purchases of intangible assets Business acquisitions, net of cash acquired Purchases of investments Proceeds from exits of investments Proceeds (payments) on maturity of foreign currency contracts Net cash provided by (used in) investing activities
$
$
Cash flows from financing activities: Proceeds from issuance of common stock, net Purchases of treasury stock Acquisition of consolidated subsidiary Taxes paid related to net share settlement of equity awards Payments of business combination contingent consideration Repayment of borrowings Dividends paid Net cash provided by (used in) financing activities $ Effect of exchange rate changes on cash $ Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period $
383,432
$
Twelve Months Ended June 30, June 30, 2026 2025
379,705
$
1,523,293
$
1,400,723
44,778 10,343 27,458
63,628 10,660 24,751
201,342 42,810 104,348
198,473 37,338 91,661
2,340 (1,000)
(1,269) 2,533
(2,382) 15,014
(3,644) 10,299
(4,353)
—
(4,353)
—
(37,209) (33,866)
(5,215) (32,133)
(96,778) (9,920)
(76,684) (80,165)
12,150
47,017
(140,260)
82,629
50,558 454,631
$
49,089 538,766
$
172,715 1,805,829
$
90,958 1,751,588
(51,127) (5,384) (739) (325,319) (2,000) —
(30,585) (3,193) — (138,578) (2,013) 250
(156,285) (18,670) (2,218) (350,724) (28,536) 2,752
(89,865) (10,777) — (139,248) (6,416) 4,628
918 (383,651) $
40,406 (133,713) $
8,482 (545,199) $
41,633 (200,045)
29,314 (200,000)
30,156 (100,008)
74,503 (700,037)
74,439 (300,025)
—
(10,855)
—
(10,855)
(388)
(590)
(21,833)
(18,077)
— (5,000) (87,090) (263,164) $ 905 $ (191,279) 1,660,513 1,469,234 $
— (5,000) (77,590) (163,887) $ 35,573 $ 276,739 932,711 1,209,450 $
— (10,000) (349,662) (1,007,029) $ 6,183 $ 259,784 1,209,450 1,469,234 $
(855) (40,000) (310,880) (606,253) 25,799 971,089 238,361 1,209,450
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 8 of 10
RESMED INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below: Three Months Ended Twelve Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 Revenue
$ 1,463,647
$ 1,347,993
$ 5,653,443
$ 5,146,327
GAAP cost of sales Less: Amortization of acquired intangibles (A) Less: Masks with magnets field safety notification expenses (A) Less: Astral field safety notification expenses (A) Non-GAAP cost of sales
$
$
527,923 (9,367)
$ 2,201,704 (31,779)
$ 2,091,357 (32,116)
1,512 —
— (41,885) $ 2,128,040
1,512 — $ 2,060,753
GAAP gross profit GAAP gross margin Non-GAAP gross profit Non-GAAP gross margin
$
$
$
602,431 (8,301) — (41,885) 552,245
$
861,216 $ 58.8 % 911,402 $ 62.3 %
520,068
820,070 $ 3,451,739 $ 3,054,970 60.8 % 61.1 % 59.4 % 827,925 $ 3,525,403 $ 3,085,574 61.4 % 62.4 % 60.0 %
The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below: Three Months Ended
Twelve Months Ended
June 30, 2026
June 30, 2025
June 30, 2026
June 30, 2025
$ 1,463,647
$ 1,347,993
$ 5,653,443
$ 5,146,327
GAAP selling, general, and administrative Less: Acquisition and portfolio review related expenses
296,283
267,156
1,119,528
993,050
(5,628)
(2,031)
(11,486)
(2,031)
Non-GAAP selling, general, and administrative
290,655
265,125
1,108,042
991,019
Revenue
(A)
As a percentage of revenue: GAAP selling, general, and administrative expenses
20.2 %
19.8 %
19.8 %
19.3 %
Non-GAAP selling, general, and administrative expenses
19.9 %
19.7 %
19.6 %
19.3 %
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 9 of 10
RESMED INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (Unaudited; $ in thousands, except for per share amounts)
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: Three Months Ended Twelve Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 GAAP income from operations Amortization of acquired intangibles—cost of sales (A) Amortization of acquired intangibles—operating expenses (A) Restructuring (A) Masks with magnets field safety notification expenses (A) Astral field safety notification expenses (A) Acquisition and portfolio review related expenses (A) Non-GAAP income from operations
$
$
448,708 8,301 10,499 — — 41,885 5,628 515,021
$
$
454,543 9,367
$
1,886,715 31,779
11,928 — (1,512) — 2,031 476,357 $
45,466 21,745 — 41,885 11,486 2,039,076
$
$
1,685,363 32,116 45,273 — (1,512) — 2,031 1,763,271
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
GAAP net income Amortization of acquired intangibles—cost of sales (A) Amortization of acquired intangibles—operating expenses (A) Restructuring expenses (A) Gain on previously held equity investment(A)
Three Months Ended June 30, 2026 June 30, 2025
Twelve Months Ended June 30, 2026 June 30, 2025
$
$
383,432 8,301 10,499
$
379,705 9,367 11,928
1,400,723 32,116 45,273
— —
21,745 (4,353)
— —
— 41,885 5,628 —
(1,512) — 2,031 (21,430)
— 41,885 11,486 —
(1,512) — 2,031 (21,430)
—
(29,976)
—
—
(17,059) 428,333 $
(5,544) 374,545 $
GAAP diluted shares outstanding GAAP diluted earnings per share Non-GAAP diluted earnings per share (A)
144,976 2.64 2.95
147,037 2.58 2.55
(A)
$
— (4,353)
Masks with magnets field safety notification expenses (A) Astral field safety notification expenses (A) Acquisition and portfolio review related expenses (A) Tax benefit from business cessation(A) Income tax effect of interest and penalties on income tax refunds (A) Income tax effect on non-GAAP adjustments (A) Non-GAAP net income (A) $
$ $
1,523,293 31,779 45,466
$ $
$ $
(39,453) 1,631,848 $
(20,448) 1,406,777
146,054 10.43 11.17
147,340 9.51 9.55
$ $
Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on previously held equity investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in addition to tax benefits from business cessation, and the tax effect of interest and penalties on tax refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 10 of 10
RESMED INC. AND SUBSIDIARIES Revenue by Product and Region (Unaudited; $ in millions, except for per share amounts) June 30, 2026 Americas (C) Devices Masks and other Total Americas (C) Rest of World (C) Devices Masks and other Total Rest of World (C) Global revenue Total Devices Total Masks and other Total Sleep and Breathing Health Residential Care Software Total
$
Rest of World (C) Devices Masks and other Total Rest of World (C) Global revenue Total Devices Total Masks and other Total Sleep and Breathing Health Residential Care Software Total
(A)
459 394 853
$
291 148 439
$
$
$
750 542 1,292
$
172 1,464
$
$ $
$
June 30, 2026 Americas (C) Devices Masks and other Total Americas (C)
Three Months Ended June 30, (A) 2025 % Change
$
433 359 792
6% 10 8
261 128 389
12 % 16 13
9% 12 10
$
694 487 1,181
8% 11 9
7% 10 8
$
167 1,348
3 9
2 8
Twelve Months Ended June 30, % (A) 2025 Change
Constant Currency (B)
$
$
(A)
1,768 1,513 3,281
$
1,124 572 1,697
$
$
$
2,892 2,085 4,978
$
676 5,653
$
$ $
$
Constant Currency (B)
1,654 1,343 2,998
7% 13 9
1,011 497 1,507
11 % 15 13
6% 9 7
$
2,665 1,840 4,505
9% 13 10
7% 12 9
$
641 5,146
5 10
4 8
$
$
(A)
Totals and subtotals may not add due to rounding.
(B)
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(C)
Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin America” and “Combined Europe, Asia, and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin America) and Rest of World (formerly Combined Europe, Asia, and other markets). The methodology for attributing revenue to these geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.
– End –
July 07, 2026 4:30pm EDT
Sharpens Resmed’s focus on high-growth sleep and connected care markets
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care.
This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem.
MatrixCare provides software solutions to more than 15,000 providers and supports skilled nursing, senior living and long-term care, life planning communities and home health and hospice care.
“Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth,” said Mick Farrell, Chairman and CEO of Resmed. “By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes and create value for our stakeholders. We are confident MatrixCare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market.”
“Frazier has spent several years evaluating the post-acute care technology sector and believes MatrixCare has established itself as a leading platform serving skilled nursing, senior living and home health and hospice providers,” said Ryan Lucero, General Partner at Frazier Healthcare Partners. “We are thrilled to partner with the MatrixCare team and plan to invest aggressively in product innovation to help providers deliver better outcomes as the post-acute care landscape continues to evolve.”
The transaction includes MatrixCare and related software offerings historically sold under the MatrixCare brand, including Healthcare First, Citus and home health and hospice solutions (collectively defined as the “MatrixCare business”). It excludes Resmed’s other software businesses, Brightree in the U.S. and MEDIFOX DAN in Germany.
The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Until closing, MatrixCare will continue to operate as part of Resmed, with no changes to customer service or support.
Resmed is providing additional information regarding this transaction through a Form 8-K furnished with the U.S. Securities and Exchange Commission (SEC). Supplementary materials related to this press release are available on Resmed’s Investor Relations website at investor.resmed.com .
Resmed will provide further updates regarding the financial impact of the transaction in its regulatory filings for the fourth quarter of its fiscal year 2026, consistent with regulatory requirements.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, WA, with an office in New York City, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier, visit www.frazierhealthcare.com/home
.
For Media
Brad Lotterman [email protected]
For Investors
Salli Schwartz [email protected]
Source: Resmed, Inc.
Released July 7, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
June 30, 2026 4:30pm EDT
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
-
Location: https://investor.resmed.com
-
Date: Thursday, August 6, 2026
-
Time: 1:30 p.m. PT / 4:30 p.m. ET
-
International: London, Thursday, August 6, 2026, 9:30 p.m. BST
Sydney, Friday, August 7, 2026, 6:30 a.m. AEST
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from August 6, 2026, until August 20, 2026, at:
- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13761408
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For investors | For media |
| +1 858.221.3304 | +1 619.510.1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released June 30, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
June 01, 2026 4:05pm EDT
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders.
The acquisition expands Resmed’s clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact for providers, patients and health systems.
Noctrix’s Nidra® Tonic Motor Activation (TOMAC) Therapy is an FDA De Novo classified, non-invasive, non-pharmacologic treatment designed to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults who have not found sufficient relief with drug therapy.3,4 For many patients, this therapy can deliver meaningful improvement in daily life and overall sleep health. 5
Noctrix has rapidly built a strong foundation of clinical validation for its breakthrough therapy, including 10 peer-reviewed publications and inclusion in the American Academy of Sleep Medicine (AASM) clinical practice guidelines for the treatment of RLS — notable achievements that reflect both scientific validation and growing clinical adoption.
“Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio,” said Mick Farrell, Chairman and CEO of Resmed. “We are excited to welcome the Noctrix team to Resmed and scale solutions that improve lives through better sleep and home health technologies.”
Resmed plans to integrate Noctrix’s technology into its portfolio of connected devices and digital health solutions to help expand access, improve care pathways and enhance patient outcomes over time.
“Since founding Noctrix, our mission has been to deliver innovative, non-pharmacologic solutions for people living with RLS who have limited treatment options,” said Shri Raghunathan, President and CEO of Noctrix Health. “Joining Resmed will help us advance that mission, enabling us to expand access to TOMAC therapy and reach more patients with a clinically validated solution that can help meaningfully improve sleep and quality of life.”
Completion of Acquisition
Resmed’s acquisition of Noctrix Health, Inc. was previously announced on April 30, 2026, during Resmed’s Q3 FY26 earnings call. Upon completion of the acquisition today, Noctrix became a wholly owned subsidiary within the Resmed group.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.
For Media
Brad Lotterman
[email protected]
For Investors
Salli Schwartz
[email protected]
[email protected]
1 McArdle N, et al. Prevalence of common sleep disorders in a middle-aged community sample. J Clin Sleep Med. 2022;18:1503–1514. (Identifies insomnia, obstructive sleep apnea, and RLS as among the most common sleep disorders).
2 Winkelman JW, Wipper B. Restless Legs Syndrome: A Review. JAMA. 2026;335(8):703–714. (~8% of adults report RLS symptoms; associated with sleep disturbance and reduced quality of life).
3 U.S. Food and Drug Administration. De Novo Classification Request: NTX100 Tonic Motor Activation System (DEN220059). 2023. (Device indicated to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults refractory to medications).
4 Ryschon AM, et al. Cost-Effectiveness of Tonic Motor Activation Therapy for RLS. Neurology and Therapy. 2023. (Identifies TOMAC as a nonpharmacologic treatment for medication-refractory RLS).
5 Winkelman JW, Wipper B. Restless Legs Syndrome: A Review. JAMA. 2026;335(8):703–714. (~8% of adults report RLS symptoms; associated with sleep disturbance and reduced quality of life).
Source: Resmed, Inc.
Released June 1, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
May 19, 2026 4:05pm EDT
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed’s webcast presentation will begin at approximately 4:40 p.m. (Central Time).
More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com . The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For investors +1 858.221.3304 [email protected] | For media +1 619.510.1281 [email protected] |
Source: Resmed, Inc.
Released May 19, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
May 19, 2026 9:00am EDT
Oura Members can take action on changes in sleep or breathing patterns through educational resources from Resmed and pathways for accessing care
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world’s leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.
At the same time, the use of wearable technology to track sleep is on the rise, increasing from 16% of adults in 20252 to 53% in 2026.3 Insights from wearable devices, including Oura Ring, can help people better understand their sleep patterns and encourage them to have informed conversations with their healthcare providers to learn more about potential sleep disorders, including obstructive sleep apnea (OSA). OSA is a chronic condition that disrupts breathing during sleep and often goes undiagnosed. In the U.S., an estimated 80% of people with OSA remain undiagnosed and untreated.4 Resmed and Oura are partnering to help close the awareness gap, turning insight into action.
Oura Members who experience a higher number of nighttime breathing disturbances can easily connect to trusted resources from Resmed, including:
- Educational resources and a sleep assessment to understand more about sleep health.
- The option to connect with an independent healthcare provider, virtually or in-person, to address their sleep concerns.
- An informative guide to support discussions with their healthcare provider.
By connecting consumer-generated wellness insights with Resmed’s sleep health resources, Resmed and Oura are helping Oura Members take a more informed next step to better understand their sleep health.
"We're at an inflection point in how people engage with their sleep health, driven by rising awareness and more accessible technology," said Dr. Carlos Nunez, chief medical officer at Resmed. "By partnering with ŌURA, we are turning insight into action by guiding people across their sleep health journey and making it easier for them to seek clinical evaluation and care if they have concerns about their sleep.”
“High-quality sleep is one of the strongest foundations for long-term health, yet many people live for years with unrecognized sleep and breathing issues," said Dr. Ricky Bloomfield, chief medical officer at Oura. “By pairing Oura’s continuous insights into sleep and nighttime breathing with Resmed’s sleep expertise, we’re giving people clearer tools and education to spot when something might be off and to more easily access care so they can better understand and act on changes in their sleep health.”
Resmed’s connection with Oura is designed to reach individuals who may not recognize their sleep issues or engage with the healthcare system, making it easier for people to learn about their sleep health and connect with clinical resources when they need it. The experience is available to users of Oura Ring Gen3 and Oura Ring 4 who have an active Oura Membership in the U.S.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
About ŌURA
ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission to shift healthcare from sick care to prevention, ŌURA supports millions of members worldwide across sleep, activity, stress, readiness, women’s health, and heart health. Scientifically validated against medical gold standards, the lightweight Oura Ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, and organizations. With 1,000 ecosystem partners across wellness and medicine, ŌURA is advancing the future of preventative health.
Founded in Finland in 2013, ŌURA has U.S. headquarters in San Francisco and E.U. headquarters in Oulu. ŌURA was last valued at approximately $11B—making it the world’s most valuable standalone wearable company. Learn more at ouraring.com or connect with ŌURA on Instagram , LinkedIn , and TikTok .
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.
Scroll to view ↔
| Contacts | |
| Resmed | |
| For Media | For Investors |
| Caela Shay | Salli Schwartz |
| [email protected] | [email protected] |
| [email protected] | [email protected] |
| Oura | |
| [email protected] | |
1 Resmed Global Sleep Survey 2026. Available at: sleepsurvey.resmed.com
2 Resmed Global Sleep Survey 2025. Available at: sleepsurvey.resmed.com
3 Resmed Global Sleep Survey 2026. Available at: sleepsurvey.resmed.com
4 Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice. Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017
Source: Resmed, Inc.
Released May 19, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
April 30, 2026 4:05pm EDT
Related Documents
Earnings WebcastAudio Transcript
- Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis
- GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%
- GAAP income from operations increased 17%; non-GAAP income from operations up 18%
- GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86
- Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.
“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.
"Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.
As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth."
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
Scroll to view ↔
| Three Months Ended | |||||||||||||
| March 31, 2026 | March 31, 2025 | % Change | Constant Currency (A) | ||||||||||
| Revenue | $ | 1,431.4 | $ | 1,291.7 | 11 | % | 8 | % | |||||
| Gross margin | 62.2 | % | 59.3 | % | 5 | ||||||||
| Non-GAAP gross margin (B) | 62.8 | % | 59.9 | % | 5 | ||||||||
| Selling, general, and administrative expenses | 285.7 | 245.3 | 16 | 11 | |||||||||
| Non-GAAP selling, general, and administrative expenses_(B)_ | 279.8 | 245.3 | 14 | 9 | |||||||||
| Research and development expenses | 94.3 | 83.9 | 12 | 8 | |||||||||
| Income from operations | 499.8 | 426.3 | 17 | ||||||||||
| Non-GAAP income from operations (B) | 524.8 | 444.6 | 18 | ||||||||||
| Net income | 398.7 | 365.0 | 9 | ||||||||||
| Non-GAAP net income (B) | 417.2 | 348.5 | 20 | ||||||||||
| Diluted earnings per share | $ | 2.74 | $ | 2.48 | 10 | ||||||||
| Non-GAAP diluted earnings per share (B) | $ | 2.86 | $ | 2.37 | 21 |
Scroll to view ↔
| Nine Months Ended | |||||||||||||
| March 31, 2026 | March 31, 2025 | % Change | Constant Currency (A) | ||||||||||
| Revenue | $ | 4,189.8 | $ | 3,798.3 | 10 | % | 8 | % | |||||
| Gross margin | 61.8 | % | 58.8 | % | 5 | ||||||||
| Non-GAAP gross margin (B) | 62.4 | % | 59.4 | % | 5 | ||||||||
| Selling, general, and administrative expenses | 823.2 | 725.9 | 13 | 10 | |||||||||
| Non-GAAP selling, general, and administrative expenses_(B)_ | 817.4 | 725.9 | 13 | 9 | |||||||||
| Research and development expenses | 272.6 | 244.8 | 11 | 9 | |||||||||
| Income from operations | 1,438.0 | 1,230.8 | 17 | ||||||||||
| Non-GAAP income from operations (B) | 1,524.1 | 1,286.9 | 18 | ||||||||||
| Net income | 1,139.9 | 1,021.0 | 12 | ||||||||||
| Non-GAAP net income (B) | 1,203.5 | 1,032.2 | 17 | ||||||||||
| Diluted earnings per share | $ | 7.79 | $ | 6.93 | 12 | ||||||||
| Non-GAAP diluted earnings per share (B) | $ | 8.22 | $ | 7.00 | 17 |
Scroll to view ↔
| (A) | In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. |
| (B) | See the reconciliation of non-GAAP financial measures in the table at the end of the press release. |
Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted
- Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories.
- Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.
- Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant currency basis.
- Residential Care Software revenue increased by 4 percent on a constant currency basis.
- Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.
- Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of $5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.
- Income from operations increased by 17 percent and non-GAAP income from operations increased by 18 percent.
- Net income for the quarter was $399 million and diluted earnings per share was $2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to $2.86, predominantly attributable to strong sales growth and gross margin improvement.
- Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of $399 million and non-GAAP net income of $417 million.
- During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration of $175 million as part of our ongoing capital management.
Other Business and Operational Highlights
- Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action.
- Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company's distribution capacity to better serve patients and providers across North America.
- Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S.
Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive.
Webcast details
Resmed will discuss its third quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||||||
| Net revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | |||||||
| Cost of sales | 532,577 | 517,883 | 1,575,796 | 1,540,684 | |||||||||||
| Amortization of acquired intangibles (1) | 7,850 | 7,444 | 23,480 | 22,748 | |||||||||||
| Total cost of sales | $ | 540,427 | $ | 525,327 | $ | 1,599,276 | $ | 1,563,432 | |||||||
| Gross profit | $ | 890,979 | $ | 766,409 | $ | 2,590,520 | $ | 2,234,902 | |||||||
| Selling, general, and administrative | 279,797 | 245,302 | 817,387 | 725,894 | |||||||||||
| Acquisition and portfolio review related expenses (1) | 5,858 | — | 5,858 | — | |||||||||||
| Total selling, general, and administrative | 285,655 | 245,302 | 823,245 | 725,894 | |||||||||||
| Research and development | 94,267 | 83,944 | 272,560 | 244,840 | |||||||||||
| Amortization of acquired intangibles (1) | 11,247 | 10,895 | 34,967 | 33,345 | |||||||||||
| Restructuring expenses (1) | — | — | 21,745 | — | |||||||||||
| Total operating expenses | $ | 391,169 | $ | 340,141 | $ | 1,152,517 | $ | 1,004,079 | |||||||
| Income from operations | $ | 499,810 | $ | 426,268 | $ | 1,438,003 | $ | 1,230,823 | |||||||
| Other income (expenses), net: | |||||||||||||||
| Interest (expense) income, net | $ | 12,287 | $ | 793 | $ | 29,029 | $ | (1,643 | ) | ||||||
| Gain (loss) attributable to equity method investments | 1,718 | 335 | 4,722 | 2,375 | |||||||||||
| Gain (loss) on equity investments | (10,130 | ) | (5,647 | ) | (16,014 | ) | (7,765 | ) | |||||||
| Other, net | (1,373 | ) | (4,056 | ) | (10,488 | ) | (4,277 | ) | |||||||
| Total other income (expenses), net | 2,502 | (8,575 | ) | 7,249 | (11,310 | ) | |||||||||
| Income before income taxes | $ | 502,312 | $ | 417,693 | $ | 1,445,252 | $ | 1,219,513 | |||||||
| Income taxes | 103,580 | 52,652 | 305,391 | 198,495 | |||||||||||
| Net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | |||||||
| Basic earnings per share | $ | 2.74 | $ | 2.49 | $ | 7.82 | $ | 6.96 | |||||||
| Diluted earnings per share | $ | 2.74 | $ | 2.48 | $ | 7.79 | $ | 6.93 | |||||||
| Non-GAAP diluted earnings per share (1) | $ | 2.86 | $ | 2.37 | $ | 8.22 | $ | 7.00 | |||||||
| Basic shares outstanding | 145,340 | 146,719 | 145,794 | 146,797 | |||||||||||
| Diluted shares outstanding | 145,723 | 147,220 | 146,369 | 147,432 |
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
Scroll to view ↔
| March 31, 2026 | June 30, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,660,513 | $ | 1,209,450 | |||
| Accounts receivable, net | 998,837 | 939,492 | |||||
| Inventories | 911,876 | 927,711 | |||||
| Prepayments and other current assets | 492,836 | 428,952 | |||||
| Total current assets | $ | 4,064,062 | $ | 3,505,605 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 566,972 | $ | 550,790 | |||
| Operating lease right-of-use assets | 161,602 | 167,497 | |||||
| Goodwill and other intangibles, net | 3,468,321 | 3,511,541 | |||||
| Deferred income taxes and other non-current assets | 523,328 | 438,958 | |||||
| Total non-current assets | $ | 4,720,223 | $ | 4,668,786 | |||
| Total assets | $ | 8,784,285 | $ | 8,174,391 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 273,301 | $ | 278,157 | |||
| Accrued expenses | 446,149 | 402,253 | |||||
| Operating lease liabilities, current | 29,233 | 30,506 | |||||
| Deferred revenue | 179,277 | 166,030 | |||||
| Income taxes payable | 163,322 | 132,274 | |||||
| Short-term debt | 259,928 | 9,900 | |||||
| Total current liabilities | $ | 1,351,210 | $ | 1,019,120 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 163,148 | $ | 156,803 | |||
| Deferred income taxes | 77,929 | 77,682 | |||||
| Operating lease liabilities, non-current | 149,840 | 153,015 | |||||
| Other long-term liabilities | 146,079 | 141,520 | |||||
| Long-term debt | 404,168 | 658,392 | |||||
| Total non-current liabilities | $ | 941,164 | $ | 1,187,412 | |||
| Total liabilities | $ | 2,292,374 | $ | 2,206,532 | |||
| Stockholders’ equity | |||||||
| Common stock | $ | 763 | $ | 761 | |||
| Additional paid-in capital | 2,134,231 | 2,033,599 | |||||
| Retained earnings | 6,958,779 | 6,081,490 | |||||
| Treasury stock | (2,576,957 | ) | (2,073,292 | ) | |||
| Accumulated other comprehensive income | (24,905 | ) | (74,699 | ) | |||
| Total stockholders’ equity | $ | 6,491,911 | $ | 5,967,859 | |||
| Total liabilities and stockholders’ equity | $ | 8,784,285 | $ | 8,174,391 | |||
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | |||||||
| Adjustment to reconcile net income to cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 58,981 | 43,675 | 156,564 | 134,845 | |||||||||||
| Amortization of right-of-use assets | 10,051 | 8,235 | 32,467 | 26,678 | |||||||||||
| Stock-based compensation costs | 26,792 | 24,120 | 76,890 | 66,910 | |||||||||||
| (Gain) loss attributable to equity method investments, net of dividends received | (1,718 | ) | (335 | ) | (4,722 | ) | (2,375 | ) | |||||||
| (Gain) loss on equity investments | 10,130 | 5,647 | 16,014 | 7,765 | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable, net | (16,857 | ) | (40,033 | ) | (59,569 | ) | (71,469 | ) | |||||||
| Inventories, net | 12,480 | 29,864 | 23,946 | (48,032 | ) | ||||||||||
| Prepaid expenses, net deferred income taxes and other current assets | (48,335 | ) | 79,357 | (152,410 | ) | 35,612 | |||||||||
| Accounts payable, accrued expenses, income taxes payable and other | 103,876 | 63,091 | 122,157 | 41,870 | |||||||||||
| Net cash provided by (used in) operating activities | $ | 554,132 | $ | 578,662 | $ | 1,351,198 | $ | 1,212,822 | |||||||
| Cash flows from investing activities: | |||||||||||||||
| Purchases of property, plant, and equipment | (33,654 | ) | (20,796 | ) | (105,158 | ) | (59,280 | ) | |||||||
| Patent registration and acquisition costs | (5,935 | ) | (2,992 | ) | (13,286 | ) | (7,584 | ) | |||||||
| Purchases of intangible assets | — | — | (1,479 | ) | — | ||||||||||
| Business acquisitions, net of cash acquired | (24,883 | ) | — | (25,405 | ) | (670 | ) | ||||||||
| Purchases of investments | (20,132 | ) | (2,053 | ) | (26,536 | ) | (4,403 | ) | |||||||
| Proceeds from exits of investments | 2,502 | — | 2,752 | 4,378 | |||||||||||
| Proceeds (payments) on maturity of foreign currency contracts | 24,074 | (5,945 | ) | 7,564 | 1,227 | ||||||||||
| Net cash provided by (used in) investing activities | $ | (58,028 | ) | $ | (31,786 | ) | $ | (161,548 | ) | $ | (66,332 | ) | |||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from issuance of common stock, net | 7,427 | 9,022 | 45,189 | 44,283 | |||||||||||
| Purchases of treasury stock | (175,013 | ) | (75,026 | ) | (500,037 | ) | (200,017 | ) | |||||||
| Taxes paid related to net share settlement of equity awards | (418 | ) | (364 | ) | (21,445 | ) | (17,487 | ) | |||||||
| Payments of business combination contingent consideration | — | — | — | (855 | ) | ||||||||||
| Repayment of borrowings | — | — | (5,000 | ) | (35,000 | ) | |||||||||
| Dividends paid | (87,238 | ) | (77,704 | ) | (262,572 | ) | (233,290 | ) | |||||||
| Net cash provided by (used in) financing activities | $ | (255,242 | ) | $ | (144,072 | ) | $ | (743,865 | ) | $ | (442,366 | ) | |||
| Effect of exchange rate changes on cash | $ | 2,582 | $ | 7,963 | $ | 5,278 | $ | (9,774 | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | 243,444 | 410,767 | 451,063 | 694,350 | |||||||||||
| Cash and cash equivalents at beginning of period | 1,417,069 | 521,944 | 1,209,450 | 238,361 | |||||||||||
| Cash and cash equivalents at end of period | $ | 1,660,513 | $ | 932,711 | $ | 1,660,513 | $ | 932,711 | |||||||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below:
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||||||
| Revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | |||||||
| GAAP cost of sales | $ | 540,427 | $ | 525,327 | $ | 1,599,276 | $ | 1,563,432 | |||||||
| Less: Amortization of acquired intangibles (A) | (7,850 | ) | (7,444 | ) | (23,480 | ) | (22,748 | ) | |||||||
| Non-GAAP cost of sales | $ | 532,577 | $ | 517,883 | $ | 1,575,796 | $ | 1,540,684 | |||||||
| GAAP gross profit | $ | 890,979 | $ | 766,409 | $ | 2,590,520 | $ | 2,234,902 | |||||||
| GAAP gross margin | 62.2 | % | 59.3 | % | 61.8 | % | 58.8 | % | |||||||
| Non-GAAP gross profit | $ | 898,829 | $ | 773,853 | $ | 2,614,000 | $ | 2,257,650 | |||||||
| Non-GAAP gross margin | 62.8 | % | 59.9 | % | 62.4 | % | 59.4 | % | |||||||
The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||||||
| Revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | |||||||
| GAAP selling, general, and administrative | 285,655 | 245,302 | 823,245 | 725,894 | |||||||||||
| Less: Acquisition and portfolio review related expenses (A) | (5,858 | ) | — | (5,858 | ) | — | |||||||||
| Non-GAAP selling, general, and administrative | 279,797 | 245,302 | 817,387 | 725,894 | |||||||||||
| As a percentage of revenue: | |||||||||||||||
| GAAP selling, general, and administrative expenses | 20.0 | % | 19.0 | % | 19.6 | % | 19.1 | % | |||||||
| Non-GAAP selling, general, and administrative expenses | 19.5 | % | 19.0 | % | 19.5 | % | 19.1 | % | |||||||
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||
| GAAP income from operations | $ | 499,810 | $ | 426,268 | $ | 1,438,003 | $ | 1,230,823 | |||
| Amortization of acquired intangibles—cost of sales (A) | 7,850 | 7,444 | 23,480 | 22,748 | |||||||
| Amortization of acquired intangibles—operating expenses (A) | 11,247 | 10,895 | 34,967 | 33,345 | |||||||
| Restructuring (A) | — | — | 21,745 | — | |||||||
| Acquisition and portfolio review related expenses (A) | 5,858 | — | 5,858 | — | |||||||
| Non-GAAP income from operations | $ | 524,765 | $ | 444,607 | $ | 1,524,053 | $ | 1,286,916 | |||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
Scroll to view ↔
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | ||||||||||||
| GAAP net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | |||||||
| Amortization of acquired intangibles—cost of sales (A) | 7,850 | 7,444 | 23,480 | 22,748 | |||||||||||
| Amortization of acquired intangibles—operating expenses (A) | 11,247 | 10,895 | 34,967 | 33,345 | |||||||||||
| Restructuring expenses (A) | — | — | 21,745 | — | |||||||||||
| Acquisition and portfolio review related expenses (A) | 5,858 | — | 5,858 | — | |||||||||||
| Income tax effect of interest and penalties on income tax refunds (A) | — | (29,976 | ) | — | (29,976 | ) | |||||||||
| Income tax effect on non-GAAP adjustments (A) | (6,519 | ) | (4,871 | ) | (22,394 | ) | (14,904 | ) | |||||||
| Non-GAAP net income (A) | $ | 417,168 | $ | 348,533 | $ | 1,203,517 | $ | 1,032,231 | |||||||
| GAAP diluted shares outstanding | 145,723 | 147,220 | 146,369 | 147,432 | |||||||||||
| GAAP diluted earnings per share | $ | 2.74 | $ | 2.48 | $ | 7.79 | $ | 6.93 | |||||||
| Non-GAAP diluted earnings per share (A) | $ | 2.86 | $ | 2.37 | $ | 8.22 | $ | 7.00 |
Scroll to view ↔
| (A) | Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. |
| Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. | |
Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)
Scroll to view ↔
| Three Months Ended | |||||||||||
| March 31, 2026 | (A) | March 31, 2025 | (A) | % Change | Constant Currency (B) | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 447.5 | $ | 422.7 | 6 | % | |||||
| Masks and other | 371.2 | 326.7 | 14 | ||||||||
| Total U.S., Canada and Latin America | $ | 818.7 | $ | 749.3 | 9 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 288.2 | $ | 253.5 | 14 | % | 6 | % | |||
| Masks and other | 153.6 | 127.7 | 20 | 10 | |||||||
| Total Combined Europe, Asia and other markets | $ | 441.8 | $ | 381.3 | 16 | 7 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 735.7 | $ | 676.2 | 9 | % | 6 | % | |||
| Total Masks and other | 524.8 | 454.4 | 15 | 12 | |||||||
| Total Sleep and Breathing Health | $ | 1,260.5 | $ | 1,130.6 | 11 | 8 | |||||
| Residential Care Software | 170.9 | 161.2 | 6 | 4 | |||||||
| Total | $ | 1,431.4 | $ | 1,291.7 | 11 | 8 | |||||
Scroll to view ↔
| Nine Months Ended | |||||||||||
| March 31, 2026 | (A) | March 31, 2025 | (A) | % Change | Constant Currency (B) | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 1,309.0 | $ | 1,221.6 | 7 | % | |||||
| Masks and other | 1,119.5 | 983.9 | 14 | ||||||||
| Total U.S., Canada and Latin America | $ | 2,428.5 | $ | 2,205.6 | 10 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 833.3 | $ | 749.6 | 11 | % | 6 | % | |||
| Masks and other | 424.2 | 368.7 | 15 | 7 | |||||||
| Total Combined Europe, Asia and other markets | $ | 1,257.4 | $ | 1,118.3 | 12 | 6 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 2,142.3 | $ | 1,971.3 | 9 | % | 7 | % | |||
| Total Masks and other | 1,543.6 | 1,352.6 | 14 | 12 | |||||||
| Total Sleep and Breathing Health | $ | 3,685.9 | $ | 3,323.9 | 11 | 9 | |||||
| Residential Care Software | 503.9 | 474.4 | 6 | 4 | |||||||
| Total | $ | 4,189.8 | $ | 3,798.3 | 10 | 8 |
Scroll to view ↔
| (A) | Totals and subtotals may not add due to rounding. |
| (B) | In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. |
Scroll to view ↔
| For investors | For media |
| +1 858-221-3304 | +1 619-510-1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released April 30, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
April 30, 2026 4:10pm EDT
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.
“After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership,” said Mick Farrell, Chairman and CEO of Resmed. “Brett’s leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creation and our goal to improve more than 500 million lives. On behalf of the Board and the entire Resmed team, I thank Brett for his exceptional contributions and wish him all the best in his well-earned retirement.”
Aaron Bloomer joins Resmed from Exact Sciences, a global leader in cancer diagnostics recently acquired by Abbott, where he served as Chief Financial Officer.
Aaron brings more than 17 years of global finance and operating leadership experience, with a strong track record of driving growth, operational discipline and shareholder value creation. At Exact Sciences, he helped shape and execute a new strategic plan that delivered strong revenue growth, significant margin expansion and substantial increases in free cash flow. Aaron also strengthened capital allocation frameworks and supported strategic M&A, as well as new product launches to expand the company’s portfolio.
Previously, Aaron held senior finance leadership roles at Baxter International and 3M. Across these roles, he drove operational rigor, improved financial performance, drove transformations and led strategic initiatives including portfolio management, acquisitions and divestitures. During his more than a decade-long tenure at 3M, he served in a variety of roles including Senior Vice President of Financial Planning and Analysis, as a regional CFO based in China and a global divisional CFO based in Japan.
“Aaron is a proven financial leader with deep experience driving operational discipline, strategic growth and global financial performance. He stood out as a star during the selection process with his intelligence and experience in growth businesses,” Mick Farrell said. “We look forward to the leadership and broad perspective Aaron will bring as we continue to execute on our 2030 strategy, scale our business and drive sustainable long-term growth.”
“I’m honored to join Resmed at such an exciting time in its journey,” said Aaron Bloomer. “Resmed’s leadership in digital health and its vision to create a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home, resonates with me. I look forward to working with the team to build on its strong foundation and support continued growth and value creation.”
Brett Sandercock will serve as an advisor to the CEO through the end of calendar year 2027.
Resmed reported results for its third quarter fiscal year 2026 today and is reiterating its outlook for fiscal year 2026, including gross margin in the range of 62-63%, SG&A expenses in the range of 19-20%, R&D expenses in the range of 6-7% and effective tax rate in the range of 21-23%.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For Investors | For Media |
| Salli Schwartz | Brad Lotterman |
| [email protected] | [email protected] |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released April 30, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
For investors ‘+1 858-221-3304 [email protected]
For media +1 619-510-1281 [email protected] ‘
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026 •
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis
•
GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%
•
GAAP income from operations increased 17%; non-GAAP income from operations up 18%
•
GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86
•
Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, April 30, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell. "Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home. As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth."
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
Page 2 of 10
Financial Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended March 31, March 31, 2026 2025 % Change $ 1,431.4 Revenue $ 1,291.7 11 % 62.2 % Gross margin 59.3 % 5 Non-GAAP gross margin (B) 62.8 % 59.9 % 5 285.7 Selling, general, and administrative expenses 245.3 16 Non-GAAP selling, general, and administrative expenses(B) 279.8 245.3 14 94.3 Research and development expenses 83.9 12 499.8 Income from operations 426.3 17 524.8 Non-GAAP income from operations (B) 444.6 18 398.7 Net income 365.0 9 (B) 417.2 Non-GAAP net income 348.5 20 $ 2.74 Diluted earnings per share $ 2.48 10 $ 2.86 Non-GAAP diluted earnings per share (B) $ 2.37 21 Nine Months Ended March 31, March 31, 2026 2025 % Change $ 4,189.8 Revenue $ 3,798.3 10 % 61.8 % Gross margin 58.8 % 5 Non-GAAP gross margin (B) 62.4 % 59.4 % 5 823.2 725.9 Selling, general, and administrative expenses 13 Non-GAAP selling, general, and administrative expenses(B) 817.4 725.9 13 272.6 Research and development expenses 244.8 11 1,438.0 Income from operations 1,230.8 17 1,524.1 Non-GAAP income from operations (B) 1,286.9 18 1,139.9 Net income 1,021.0 12 (B) 1,203.5 Non-GAAP net income 1,032.2 17 $ 7.79 Diluted earnings per share $ 6.93 12 $ 8.22 Non-GAAP diluted earnings per share (B) $ 7.00 17
Constant Currency (A) 8%
11 9 8
Constant Currency (A) 8%
10 9 9
(A)
In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B)
See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Discussion of Third Quarter Results All comparisons are to the prior year period unless otherwise noted
•
Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories. ◦
Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.
◦
Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant currency basis.
◦
Residential Care Software revenue increased by 4 percent on a constant currency basis.
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
•
Page 3 of 10
Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.
•
Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of $5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.
•
Income from operations increased by 17 percent and non-GAAP income from operations increased by 18 percent.
•
Net income for the quarter was $399 million and diluted earnings per share was $2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to $2.86, predominantly attributable to strong sales growth and gross margin improvement.
•
Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of $399 million and non-GAAP net income of $417 million.
•
During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration of $175 million as part of our ongoing capital management.
Other Business and Operational Highlights •
Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action.
•
Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company's distribution capacity to better serve patients and providers across North America.
•
Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S.
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
Page 4 of 10
Dividend program The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive. Webcast details Resmed will discuss its third quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026. About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed. Safe harbor statement Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements. – More –
Page 5 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited; $ in thousands, except for per share amounts) Three Months Ended March 31, March 31, 2026 2025 Net revenue Cost of sales Amortization of acquired intangibles (1) Total cost of sales Gross profit
$
1,431,406
$ $
532,577 7,850 540,427 890,979
$
1,291,736
$ $
517,883 7,444 525,327 766,409
Nine Months Ended March 31, March 31, 2026 2025 $
4,189,796
$ $
1,575,796 23,480 1,599,276 2,590,520
$
3,798,334
$ $
1,540,684 22,748 1,563,432 2,234,902
Selling, general, and administrative Acquisition and portfolio review related expenses (1) Total selling, general, and administrative
279,797
245,302
817,387
725,894
5,858 285,655
— 245,302
5,858 823,245
— 725,894
Research and development Amortization of acquired intangibles (1) Restructuring expenses (1) Total operating expenses Income from operations
$ $
94,267 11,247 — 391,169 499,810
$ $
83,944 10,895 — 340,141 426,268
$ $
272,560 34,967 21,745 1,152,517 1,438,003
$ $
244,840 33,345 — 1,004,079 1,230,823
$
12,287
$
793
$
29,029
$
(1,643)
Other income (expenses), net: Interest (expense) income, net Gain (loss) attributable to equity method investments Gain (loss) on equity investments Other, net Total other income (expenses), net Income before income taxes Income taxes Net income Basic earnings per share Diluted earnings per share Non-GAAP diluted earnings per share (1) Basic shares outstanding Diluted shares outstanding
1,718
335
4,722
$
(10,130) (1,373) 2,502 502,312 $ 103,580 398,732 $
(5,647) (4,056) (8,575) 417,693 $ 52,652 365,041 $
(16,014) (10,488) 7,249 1,445,252 $ 305,391 1,139,861 $
$ $ $
2.74 2.74 2.86
2.49 2.48 2.37
7.82 7.79 8.22
$
145,340 145,723
$ $ $
$ $ $
146,719 147,220
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
– More –
145,794 146,369
2,375
$ $ $
(7,765) (4,277) (11,310) 1,219,513 198,495 1,021,018 6.96 6.93 7.00 146,797 147,432
Page 6 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited; $ in thousands) March 31, 2026 Assets Current assets: Cash and cash equivalents Accounts receivable, net Inventories Prepayments and other current assets Total current assets Non-current assets: Property, plant, and equipment, net Operating lease right-of-use assets Goodwill and other intangibles, net Deferred income taxes and other non-current assets Total non-current assets Total assets Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Accrued expenses Operating lease liabilities, current Deferred revenue Income taxes payable Short-term debt Total current liabilities Non-current liabilities: Deferred revenue Deferred income taxes Operating lease liabilities, non-current Other long-term liabilities Long-term debt Total non-current liabilities Total liabilities Stockholders’ equity Common stock Additional paid-in capital Retained earnings Treasury stock Accumulated other comprehensive income Total stockholders’ equity Total liabilities and stockholders’ equity
$
$ $
$ $
$
$ $
$ $ $
$ $
– More –
June 30, 2025
1,660,513 998,837 911,876 492,836 4,064,062
$
566,972 161,602 3,468,321 523,328 4,720,223 8,784,285
$
273,301 446,149 29,233 179,277 163,322 259,928 1,351,210
$
163,148 77,929 149,840 146,079 404,168 941,164 2,292,374
$
$
$ $
$
1,209,450 939,492 927,711 428,952 3,505,605 550,790 167,497 3,511,541 438,958 4,668,786 8,174,391
278,157 402,253 30,506 166,030 132,274 9,900 1,019,120
$ $
156,803 77,682 153,015 141,520 658,392 1,187,412 2,206,532
763 $ 2,134,231 6,958,779 (2,576,957) (24,905) 6,491,911 $ 8,784,285 $
761 2,033,599 6,081,490 (2,073,292) (74,699) 5,967,859 8,174,391
Page 7 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited; $ in thousands) Three Months Ended March 31, March 31, 2026 2025 Cash flows from operating activities: Net income Adjustment to reconcile net income to cash provided by operating activities: Depreciation and amortization Amortization of right-of-use assets Stock-based compensation costs (Gain) loss attributable to equity method investments, net of dividends received (Gain) loss on equity investments Changes in operating assets and liabilities: Accounts receivable, net Inventories, net Prepaid expenses, net deferred income taxes and other current assets Accounts payable, accrued expenses, income taxes payable and other Net cash provided by (used in) operating activities Cash flows from investing activities: Purchases of property, plant, and equipment Patent registration and acquisition costs Purchases of intangible assets Business acquisitions, net of cash acquired Purchases of investments Proceeds from exits of investments Proceeds (payments) on maturity of foreign currency contracts Net cash provided by (used in) investing activities Cash flows from financing activities: Proceeds from issuance of common stock, net Purchases of treasury stock Taxes paid related to net share settlement of equity awards Payments of business combination contingent consideration Repayment of borrowings Dividends paid Net cash provided by (used in) financing activities Effect of exchange rate changes on cash Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period
$
$
$
$ $
$
398,732
$
365,041
Nine Months Ended March 31, March 31, 2026 2025 $
1,139,861
$
1,021,018
58,981 10,051 26,792
43,675 8,235 24,120
156,564 32,467 76,890
134,845 26,678 66,910
(1,718) 10,130
(335) 5,647
(4,722) 16,014
(2,375) 7,765
(16,857) 12,480
(40,033) 29,864
(59,569) 23,946
(71,469) (48,032)
(48,335)
79,357
(152,410)
35,612
103,876 554,132
$
63,091 578,662
$
122,157 1,351,198
$
41,870 1,212,822
(33,654) (5,935) — (24,883) (20,132) 2,502
(20,796) (2,992) — — (2,053) —
(105,158) (13,286) (1,479) (25,405) (26,536) 2,752
(59,280) (7,584) — (670) (4,403) 4,378
24,074 (58,028) $
(5,945) (31,786) $
7,564 (161,548) $
1,227 (66,332)
7,427 (175,013)
9,022 (75,026)
45,189 (500,037)
44,283 (200,017)
(418)
(364)
(21,445)
(17,487)
— — (87,238) (255,242) $ 2,582 $ 243,444 1,417,069 1,660,513 $
— — (77,704) (144,072) $ 7,963 $ 410,767 521,944 932,711 $
— (5,000) (262,572) (743,865) $ 5,278 $ 451,063 1,209,450 1,660,513 $
(855) (35,000) (233,290) (442,366) (9,774) 694,350 238,361 932,711
– More –
Page 8 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below: Three Months Ended March 31, March 31, 2026 2025
Nine Months Ended March 31, March 31, 2026 2025
Revenue
$ 1,431,406
$ 1,291,736
$ 4,189,796
$ 3,798,334
GAAP cost of sales Less: Amortization of acquired intangibles (A) Non-GAAP cost of sales
$
$
$ 1,599,276 (23,480) $ 1,575,796
$ 1,563,432 (22,748) $ 1,540,684
GAAP gross profit GAAP gross margin Non-GAAP gross profit Non-GAAP gross margin
$
$
$
540,427 (7,850) 532,577
$
890,979 $ 62.2 % 898,829 $ 62.8 %
525,327 (7,444) 517,883
766,409 $ 2,590,520 $ 2,234,902 59.3 % 61.8 % 58.8 % 773,853 $ 2,614,000 $ 2,257,650 59.9 % 62.4 % 59.4 %
The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:
Revenue
Three Months Ended March 31, March 31, 2026 2025 $ 1,431,406 $ 1,291,736
GAAP selling, general, and administrative Less: Acquisition and portfolio review related expenses (A) Non-GAAP selling, general, and administrative
285,655 (5,858) 279,797
As a percentage of revenue: GAAP selling, general, and administrative expenses Non-GAAP selling, general, and administrative expenses
Nine Months Ended March 31, March 31, 2026 2025 $ 4,189,796 $ 3,798,334
245,302 — 245,302
20.0 % 19.5 %
823,245 (5,858) 817,387
19.0 % 19.0 %
725,894 — 725,894
19.6 % 19.5 %
19.1 % 19.1 %
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: Three Months Ended March 31, March 31, 2026 2025 GAAP income from operations Amortization of acquired intangibles—cost of sales (A) Amortization of acquired intangibles—operating expenses (A) Restructuring (A) Acquisition and portfolio review related expenses (A) Non-GAAP income from operations
$
$
499,810 7,850 11,247 — 5,858 524,765
$
$
426,268 7,444 10,895 — — 444,607
Nine Months Ended March 31, March 31, 2026 2025 $
$
1,438,003 23,480 34,967 21,745 5,858 1,524,053
$
$
1,230,823 22,748 33,345 — — 1,286,916
Page 9 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES – More –
Reconciliation of Non-GAAP Financial Measures (Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: Three Months Ended March 31, March 31, 2026 2025 GAAP net income Amortization of acquired intangibles—cost of sales (A) Amortization of acquired intangibles—operating expenses (A) Restructuring expenses (A) Acquisition and portfolio review related expenses (A) Income tax effect of interest and penalties on income tax refunds (A) Income tax effect on non-GAAP adjustments (A) Non-GAAP net income (A) GAAP diluted shares outstanding GAAP diluted earnings per share Non-GAAP diluted earnings per share (A) (A)
$
398,732 7,850 11,247
$
365,041 7,444 10,895
Nine Months Ended March 31, March 31, 2026 2025 $
1,139,861 23,480 34,967
$
1,021,018 22,748 33,345
— 5,858
— —
21,745 5,858
— —
—
(29,976)
—
(29,976)
$
(6,519) 417,168 $
(4,871) 348,533 $
$ $
145,723 2.74 2.86
147,220 2.48 2.37
$ $
$ $
(22,394) 1,203,517 $
(14,904) 1,032,231
146,369 7.79 8.22
147,432 6.93 7.00
$ $
Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
– More –
Page 10 of 10
RMD Third Quarter 2026 Earnings Press Release – April 30, 2026
RESMED INC. AND SUBSIDIARIES Revenue by Product and Region (Unaudited; $ in millions, except for per share amounts)
March 31, 2026 U.S., Canada, and Latin America Devices Masks and other Total U.S., Canada and Latin America Combined Europe, Asia, and other markets Devices Masks and other Total Combined Europe, Asia and other markets Global revenue Total Devices Total Masks and other Total Sleep and Breathing Health Residential Care Software Total
$
Combined Europe, Asia, and other markets Devices Masks and other Total Combined Europe, Asia and other markets Global revenue Total Devices Total Masks and other Total Sleep and Breathing Health Residential Care Software Total
(A)
447.5 371.2 818.7
$
288.2 153.6 441.8
$
$
$
735.7 524.8 1,260.5
$
170.9 1,431.4
$
$ $
$
March 31, 2026 U.S., Canada, and Latin America Devices Masks and other Total U.S., Canada and Latin America
Three Months Ended March 31, (A) 2025 % Change
$
422.7 326.7 749.3
6% 14 9
253.5 127.7 381.3
14 % 20 16
6% 10 7
$
676.2 454.4 1,130.6
9% 15 11
6% 12 8
$
161.2 1,291.7
6 11
4 8
Nine Months Ended March 31, % (A) 2025 Change
Constant Currency (B)
$
$
(A)
1,309.0 1,119.5 2,428.5
$
833.3 424.2 1,257.4
$
$
$
2,142.3 1,543.6 3,685.9
$
503.9 4,189.8
$
$ $
$
Constant Currency (B)
1,221.6 983.9 2,205.6
7% 14 10
749.6 368.7 1,118.3
11 % 15 12
6% 7 6
$
1,971.3 1,352.6 3,323.9
9% 14 11
7% 12 9
$
474.4 3,798.3
6 10
4 8
$
$
(A)
Totals and subtotals may not add due to rounding.
(B)
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
– End –
April 01, 2026 4:05pm EDT
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
Scroll to view ↔
| • | Location: | https://investor.resmed.com |
| • | Date: | 1:30 p.m. PT / 4:30 p.m. ET |
| • | Time: | London, Thursday, April 30, 2026, 9:30 p.m. BST |
| • | International: | Sydney, Friday, May 1, 2026, 6:30 a.m. AEST |
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 30, 2026, until May 14, 2026, at:
- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13759381
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For investors | For media |
| +1 858.221.3304 | +1 619.510.1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released April 1, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
March 03, 2026 3:00am EST
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains
- 53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead of diet and exercise.
- Over half of respondents get quality sleep on only four nights a week or less.
- While 66% of people surveyed say they would seek medical help for ongoing sleep issues, just 23% actually do.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today unveiled the findings from its sixth annual Global Sleep Survey .
Drawing insights from 30,000 people across 13 countries, the survey reveals a widening gap between recognition of sleep’s importance and action to improve sleep health. While over half (53%) of respondents rank sleep as the most important contributor to long-term health compared to diet and exercise, many are not taking meaningful steps to improve their sleep quality.
Sleep is increasingly recognized as a key pillar of long-term health1, with 84% of respondents worldwide understanding that consistent, quality sleep can help extend a healthy lifespan. However, awareness has not translated into consistent results. The majority of respondents (53%) report getting a good night’s sleep only four nights a week or fewer, highlighting the persistent gap between knowing sleep is critical and being able to prioritize it as part of a healthy lifestyle.
As sleep awareness grows, so does the opportunity to turn intent into action.
-
Increased Wearable Use Raises Sleep Awareness Higher Than Ever: Wearable use for sleep tracking has surged among respondents, increasing from 16% in 20252 to 53% in 2026. Smartwatches lead the way, with 58% of respondents globally using them to track their sleep. Among wearable users, 62% say they would seek medical advice if their device flagged a potential risk.
-
Following Through on Healthcare Provider Conversations Remains a Challenge: While 66% of respondents say they would consult a healthcare provider for persistent sleep issues, only 23% have done so. Fewer than half (46%) of survey respondents say a healthcare provider has asked about sleep during a routine visit.
The findings suggest a clear opportunity to improve education, screening and diagnosis so more people can identify sleep issues earlier and access pathways to care.
How Daily Life Disrupts Sleep
The survey also highlights the everyday pressures shaping sleep patterns worldwide.
-
Closing the Sleep Gap for Women: Nearly half of women surveyed (48%) struggle to fall asleep, up from 38% in 2025.2 For 42% of women surveyed, stress and anxiety are key barriers to consistent, quality sleep compared with over one third (36%) of men surveyed. Family responsibilities widen the gender gap further, negatively affecting sleep for 39% of women versus 33% of men.
-
Recognizing Sleep as a Mental Health Essential: Insufficient sleep is linked to higher risk of anxiety and depression across age groups.3 This is reflected in our survey, which shows after a poor night’s sleep, more than a third of respondents report higher levels of irritability (36%) and stress (33%). Feelings of depression also increased for a quarter of respondents globally (25%).
-
Making Sleep a Workplace Priority: More than half of respondents (58%) agree that heavy workloads negatively affect their sleep. 70% of respondents report taking a “snooze day” — calling in sick after a poor night’s sleep. At the same time, 59% say flexible working arrangements help them better manage their sleep.
-
Improving Sleep in Shared Spaces: Sleeping together is associated with stronger intimacy, with 53% of respondents reporting a positive impact on their sex life compared to 23% of those who sleep apart. However, disruption is common: 39% of respondents say their partner interrupts their sleep at least weekly, and 80% experience some level of partner-related sleep disruption.
“People are increasingly recognizing sleep as a cornerstone to long-term health, which is encouraging,” said Dr. Carlos Nunez, Chief Medical Officer at Resmed. “But recognition alone is not enough. We need to help people move from awareness to action by addressing everyday barriers and improving access to screening, support and care.”
Are you getting enough sleep? Read the full 2026 Resmed Global Sleep Survey report to learn more about the trends impacting the way we sleep. To assess your sleep health, take our online sleep assessment.
Survey Methodology
Resmed commissioned an independent survey of 30,000 individuals across 13 markets: the United States (5,000), China (5,000), India (5,000), United Kingdom (2,000), Germany (2,000), France (2,000), Australia (1,500), Japan (1,500), Korea (1,500), Brazil (1,500), Poland (1,000), Singapore (1,000), and Mexico (1,000). The survey was developed in partnership with The Sleep Health Foundation (Australia) and The Sleep Charity (UK), leveraging their expertise to help identify and refine key focus areas. Samples within each country were representative of national gender and age distributions. The survey was fielded by Cint from 11 December 2025 to 14 January 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For Media | For Investors |
| Cassie-Anne Low | Salli Schwartz |
| [email protected] | [email protected] |
_______________________________
1 Resmed Global Sleep Survey 2026. Available at: sleepsurvey.resmed.com (Accessed March 2026)
2 Resmed Global Sleep Survey 2025. Available at: sleepsurvey.resmed.com (Accessed February 2026)
3 Li Y, et al. Sleep Med Rev. 2019;42:69–89
Source: Resmed, Inc.
Released March 3, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
February 24, 2026 9:00am EST
Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America.
The Greenwood center will operate as a major logistics hub, enhancing the delivery of essential healthcare products across North America while reinforcing Resmed’s commitment to the local Greenwood community. It's estimated that the facility will employ more than 100 full-time and contingent workers over time across operations, logistics and management. Resmed is working closely with local and state partners, including the State of Indiana and the City of Greenwood, to support job creation and advance the project.
The Greenwood center complements Resmed’s existing distribution centers in Atlanta, Georgia and Moreno Valley, California. Its central location will connect coastal operations and support ongoing improvements in efficiency, productivity and delivery speed. Once fully operational, it will improve two-day transit coverage across North America from 75% to 90% and shorten delivery times to Canada by one full day.
“We’re proud to grow our U.S. footprint and invest in the local Greenwood community,” said Shane Azzi, chief supply chain officer at Resmed. “Greenwood’s talented workforce and strong spirit of collaboration played a major role in our decision to locate here. The new distribution center will help us deliver products more quickly, strengthen our ability to serve patients and providers and support the region’s long term growth.”
"Indiana’s life sciences sector continues to attract new global and innovative leaders to the state,” said Indiana Governor Mike Braun. “Here in the crossroads of the U.S., Resmed will be centrally located and have access to robust infrastructure, helping the company serve customers more quickly and deliver life-changing solutions.”
“Resmed’s decision to locate in Greenwood is a win for our residents and our local economy,” said Mark W. Myers, Mayor of Greenwood. “This investment reflects our pride in bringing high-quality jobs to Greenwood and expanding the region’s role in delivering essential healthcare products nationwide. We’re grateful that Resmed chose Greenwood as the home for this new operation.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Scroll to view ↔
| For Media | For Investors |
| Caela Shay | Salli Schwartz |
| [email protected] | [email protected] |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released February 24, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
+1 858-221-3304 +1 619-510-1281
[email protected] [email protected]
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis
• Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%
• Income from operations increased 18%; non-GAAP income from operations up 19%
• Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81
• Operating cash flow of $340 million
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, January 29, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2025.
“Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home,” said Resmed’s Chairman and CEO, Mick Farrell.
January 29, 2026 4:05pm EST
Related Documents
Earnings WebcastAudio Transcript
- Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis
- Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%
- Income from operations increased 18%; non-GAAP income from operations up 19%
- Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81
- Operating cash flow of $340 million
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2025.
“Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home,” said Resmed’s Chairman and CEO, Mick Farrell.
“Year-over-year, we delivered 11% headline revenue growth, 310 basis points of non‑GAAP gross margin expansion, and continued operating excellence, resulting in another quarter of mid-teens non‑GAAP EPS growth. These results reflect strong ongoing demand for our market‑leading sleep and respiratory care devices, as well as the growing impact of our digital health ecosystem that spans more than 140 countries.
As we move into the second half of fiscal year 2026, we will continue to invest in innovation to scale our digital health capabilities and expand global access to life-saving care, while delivering sustainable, profitable growth."
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
Scroll to view ↔
| Three Months Ended | |||||||||||||
| December 31, 2025 | December 31, 2024 | % Change | Constant Currency_(A)_ | ||||||||||
| Revenue | $ | 1,422.8 | $ | 1,282.1 | 11 | % | 9 | % | |||||
| Gross margin | 61.8 | % | 58.6 | % | 5 | ||||||||
| Non-GAAP gross margin_(B)_ | 62.3 | % | 59.2 | % | 5 | ||||||||
| Selling, general, and administrative expenses | 278.4 | 241.6 | 15 | 12 | |||||||||
| Research and development expenses | 91.0 | 81.4 | 12 | 10 | |||||||||
| Income from operations | 491.7 | 417.2 | 18 | ||||||||||
| Non-GAAP income from operations_(B)_ | 517.2 | 435.9 | 19 | ||||||||||
| Net income | 392.6 | 344.6 | 14 | ||||||||||
| Non-GAAP net income_(B)_ | 411.5 | 358.3 | 15 | ||||||||||
| Diluted earnings per share | $ | 2.68 | $ | 2.34 | 15 | ||||||||
| Non-GAAP diluted earnings per share_(B)_ | $ | 2.81 | $ | 2.43 | 16 |
Scroll to view ↔
| Six Months Ended | |||||||||||||
| December 31, 2025 | December 31, 2024 | % Change | Constant Currency_(A)_ | ||||||||||
| Revenue | $ | 2,758.4 | $ | 2,506.6 | 10 | % | 8 | % | |||||
| Gross margin | 61.6 | % | 58.6 | % | 5 | ||||||||
| Non-GAAP gross margin_(B)_ | 62.2 | % | 59.2 | % | 5 | ||||||||
| Selling, general, and administrative expenses | 537.6 | 480.6 | 12 | 10 | |||||||||
| Research and development expenses | 178.3 | 160.9 | 11 | 10 | |||||||||
| Income from operations | 938.2 | 804.6 | 17 | ||||||||||
| Non-GAAP income from operations_(B)_ | 999.3 | 842.3 | 19 | ||||||||||
| Net income | 741.1 | 656.0 | 13 | ||||||||||
| Non-GAAP net income_(B)_ | 786.4 | 683.7 | 15 | ||||||||||
| Diluted earnings per share | $ | 5.05 | $ | 4.45 | 13 | ||||||||
| Non-GAAP diluted earnings per share_(B)_ | $ | 5.36 | $ | 4.63 | 16 |
Scroll to view ↔
| (A) | In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. |
| (B) | See the reconciliation of non-GAAP financial measures in the table at the end of the press release. |
Discussion of Second Quarter Results
All comparisons are to the prior year period unless otherwise noted
- Revenue grew by 9 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories.
- Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 11 percent.
- Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 6 percent on a constant currency basis.
- Residential Care Software revenue increased by 5 percent on a constant currency basis.
- Gross margin increased by 320 basis points primarily driven by manufacturing and logistics efficiencies and component cost improvements. Non-GAAP gross margin increased by 310 basis points due to the same factors.
- Selling, general, and administrative expenses increased by 12 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. SG&A expenses were 19.6 percent of revenue in the quarter, compared with 18.8 percent in the same period of the prior year.
- We recorded $6 million of restructuring-related charges following the finalization of our company-wide workforce planning activities undertaken in the first quarter of the fiscal year. Restructuring charges were comprised of employee severance and other one-time termination benefits.
- Income from operations increased by 18 percent and non-GAAP income from operations increased by 19 percent.
- Net income for the quarter was $393 million and diluted earnings per share was $2.68. Non-GAAP net income increased by 15 percent to $411 million, and non-GAAP diluted earnings per share increased by 16 percent to $2.81, predominantly attributable to strong sales growth and gross margin improvement.
- Operating cash flow for the quarter was $340 million, compared to net income in the current quarter of $393 million and non-GAAP net income of $411 million.
- During the quarter, we paid $88 million in dividends to shareholders and repurchased 704,000 shares for consideration of $175 million as part of our ongoing capital management.
Other Business and Operational Highlights
- Published new research in SLEEP (N=370,000+) showing in patients with OSA across all comorbidity cohorts each additional hour of PAP use linked to a 4.1-6.2% reduction in healthcare utilization over 12-24 months (p < 0.0001).
- Announced it received FDA clearance for an AI-enabled digital medical device, to be marketed as Smart Comfort, designed to personalize CPAP comfort settings and improve patient adherence.
- Presented at the J.P. Morgan Healthcare Conference, highlighting its long-term growth opportunities, connected-care ecosystem, and continued leadership in digital sleep and respiratory health.
Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be February 11, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from February 11, 2026, through February 12, 2026, inclusive.
Webcast details
Resmed will discuss its second quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com
. Please go to this section of the website and click on the icon for the “Q2 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13757750. The telephone replay will be available until February 12, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
Scroll to view ↔
| Three Months Ended | Six Months Ended | ||||||||||||||
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | ||||||||||||
| Net revenue | $ | 1,422,808 | $ | 1,282,089 | $ | 2,758,390 | $ | 2,506,598 | |||||||
| Cost of sales | 536,276 | 523,180 | 1,043,217 | 1,022,800 | |||||||||||
| Amortization of acquired intangibles_(1)_ | 7,808 | 7,634 | 15,630 | 15,304 | |||||||||||
| Total cost of sales | $ | 544,084 | $ | 530,814 | $ | 1,058,847 | $ | 1,038,104 | |||||||
| Gross profit | $ | 878,724 | $ | 751,275 | $ | 1,699,543 | $ | 1,468,494 | |||||||
| Selling, general, and administrative | 278,396 | 241,613 | 537,590 | 480,592 | |||||||||||
| Research and development | 90,969 | 81,372 | 178,292 | 160,897 | |||||||||||
| Amortization of acquired intangibles_(1)_ | 11,764 | 11,047 | 23,721 | 22,451 | |||||||||||
| Restructuring expenses_(1)_ | 5,935 | — | 21,745 | — | |||||||||||
| Total operating expenses | $ | 387,064 | $ | 334,032 | $ | 761,348 | $ | 663,940 | |||||||
| Income from operations | $ | 491,660 | $ | 417,243 | $ | 938,195 | $ | 804,554 | |||||||
| Other income (expenses), net: | |||||||||||||||
| Interest (expense) income, net | $ | 7,949 | $ | (775 | ) | $ | 16,742 | $ | (2,436 | ) | |||||
| Gain (loss) attributable to equity method investments | 1,515 | 1,077 | 3,004 | 2,040 | |||||||||||
| Gain (loss) on equity investments | 306 | (1,439 | ) | (5,884 | ) | (2,119 | ) | ||||||||
| Other, net | (5,282 | ) | 2,216 | (9,117 | ) | (219 | ) | ||||||||
| Total other income (expenses), net | 4,488 | 1,079 | 4,745 | (2,734 | ) | ||||||||||
| Income before income taxes | $ | 496,148 | $ | 418,322 | $ | 942,940 | $ | 801,820 | |||||||
| Income taxes | 103,555 | 73,700 | 201,811 | 145,843 | |||||||||||
| Net income | $ | 392,593 | $ | 344,622 | $ | 741,129 | $ | 655,977 | |||||||
| Basic earnings per share | $ | 2.69 | $ | 2.35 | $ | 5.08 | $ | 4.47 | |||||||
| Diluted earnings per share | $ | 2.68 | $ | 2.34 | $ | 5.05 | $ | 4.45 | |||||||
| Non-GAAP diluted earnings per share_(1)_ | $ | 2.81 | $ | 2.43 | $ | 5.36 | $ | 4.63 | |||||||
| Basic shares outstanding | 145,842 | 146,810 | 146,012 | 146,835 | |||||||||||
| Diluted shares outstanding | 146,372 | 147,481 | 146,633 | 147,520 | |||||||||||
| (1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release. | |||||||||||||||
**
Condensed Consolidated Balance Sheets**
(Unaudited; $ in thousands)
Scroll to view ↔
| December 31, 2025 | June 30, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,417,069 | $ | 1,209,450 | |||
| Accounts receivable, net | 985,634 | 939,492 | |||||
| Inventories | 922,045 | 927,711 | |||||
| Prepayments and other current assets | 494,053 | 428,952 | |||||
| Total current assets | $ | 3,818,801 | $ | 3,505,605 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 564,254 | $ | 550,790 | |||
| Operating lease right-of-use assets | 165,916 | 167,497 | |||||
| Goodwill and other intangibles, net | 3,474,610 | 3,511,541 | |||||
| Deferred income taxes and other non-current assets | 479,789 | 438,958 | |||||
| Total non-current assets | $ | 4,684,569 | $ | 4,668,786 | |||
| Total assets | $ | 8,503,370 | $ | 8,174,391 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 250,406 | $ | 278,157 | |||
| Accrued expenses | 391,500 | 402,253 | |||||
| Operating lease liabilities, current | 29,759 | 30,506 | |||||
| Deferred revenue | 176,050 | 166,030 | |||||
| Income taxes payable | 140,493 | 132,274 | |||||
| Short-term debt | 259,906 | 9,900 | |||||
| Total current liabilities | $ | 1,248,114 | $ | 1,019,120 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 159,789 | $ | 156,803 | |||
| Deferred income taxes | 77,994 | 77,682 | |||||
| Operating lease liabilities, non-current | 154,133 | 153,015 | |||||
| Other long-term liabilities | 138,538 | 141,520 | |||||
| Long-term debt | 403,923 | 658,392 | |||||
| Total non-current liabilities | $ | 934,377 | $ | 1,187,412 | |||
| Total liabilities | $ | 2,182,491 | $ | 2,206,532 | |||
| Stockholders’ equity | |||||||
| Common stock | $ | 763 | $ | 761 | |||
| Additional paid-in capital | 2,102,992 | 2,033,599 | |||||
| Retained earnings | 6,647,285 | 6,081,490 | |||||
| Treasury stock | (2,400,298 | ) | (2,073,292 | ) | |||
| Accumulated other comprehensive income | (29,863 | ) | (74,699 | ) | |||
| Total stockholders’ equity | $ | 6,320,879 | $ | 5,967,859 | |||
| Total liabilities and stockholders’ equity | $ | 8,503,370 | $ | 8,174,391 | |||
**
Condensed Consolidated Statements of Cash Flows**
(Unaudited; $ in thousands)
Scroll to view ↔
| Three Months Ended | Six Months Ended | ||||||||||||||
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | ||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 392,593 | $ | 344,622 | $ | 741,129 | $ | 655,977 | |||||||
| Adjustment to reconcile net income to cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 49,885 | 46,439 | 97,583 | 91,169 | |||||||||||
| Amortization of right-of-use assets | 12,445 | 9,463 | 22,416 | 18,443 | |||||||||||
| Stock-based compensation costs | 28,938 | 22,634 | 50,098 | 42,790 | |||||||||||
| (Gain) loss attributable to equity method investments, net of dividends received | (1,515 | ) | (1,077 | ) | (3,004 | ) | (2,040 | ) | |||||||
| (Gain) loss on equity investments | (306 | ) | 1,439 | 5,884 | 2,119 | ||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable, net | (72,682 | ) | (67,853 | ) | (42,712 | ) | (31,436 | ) | |||||||
| Inventories, net | 26,129 | (7,641 | ) | 11,466 | (77,895 | ) | |||||||||
| Prepaid expenses, net deferred income taxes and other current assets | (106,387 | ) | (43,623 | ) | (104,075 | ) | (43,746 | ) | |||||||
| Accounts payable, accrued expenses, income taxes payable and other | 10,645 | 4,219 | 18,281 | (21,220 | ) | ||||||||||
| Net cash provided by (used in) operating activities | $ | 339,745 | $ | 308,622 | $ | 797,066 | $ | 634,161 | |||||||
| Cash flows from investing activities: | |||||||||||||||
| Purchases of property, plant, and equipment | (28,539 | ) | (20,644 | ) | (71,504 | ) | (38,484 | ) | |||||||
| Patent registration and acquisition costs | (4,537 | ) | (2,825 | ) | (7,351 | ) | (4,592 | ) | |||||||
| Purchases of intangible assets | (1,479 | ) | — | (1,479 | ) | — | |||||||||
| Business acquisitions, net of cash acquired | — | (670 | ) | (522 | ) | (670 | ) | ||||||||
| Purchases of investments | (4,231 | ) | (1,000 | ) | (6,404 | ) | (2,350 | ) | |||||||
| Proceeds from exits of investments | 250 | 250 | 250 | 4,378 | |||||||||||
| Proceeds (payments) on maturity of foreign currency contracts | (12,406 | ) | (11,803 | ) | (16,510 | ) | 7,172 | ||||||||
| Net cash provided by (used in) investing activities | $ | (50,942 | ) | $ | (36,692 | ) | $ | (103,520 | ) | $ | (34,546 | ) | |||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from issuance of common stock, net | 29,557 | 26,877 | 37,762 | 35,260 | |||||||||||
| Purchases of treasury stock | (175,014 | ) | (74,986 | ) | (325,024 | ) | (124,991 | ) | |||||||
| Taxes paid related to net share settlement of equity awards | (20,308 | ) | (16,734 | ) | (21,027 | ) | (17,123 | ) | |||||||
| Payments of business combination contingent consideration | — | — | — | (855 | ) | ||||||||||
| Repayment of borrowings | (5,000 | ) | (5,000 | ) | (5,000 | ) | (35,000 | ) | |||||||
| Dividends paid | (87,584 | ) | (77,695 | ) | (175,334 | ) | (155,586 | ) | |||||||
| Net cash provided by (used in) financing activities | $ | (258,349 | ) | $ | (147,538 | ) | $ | (488,623 | ) | $ | (298,295 | ) | |||
| Effect of exchange rate changes on cash | $ | 2,767 | $ | (28,809 | ) | $ | 2,696 | $ | (17,737 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | 33,221 | 95,583 | 207,619 | 283,583 | |||||||||||
| Cash and cash equivalents at beginning of period | 1,383,848 | 426,361 | 1,209,450 | 238,361 | |||||||||||
| Cash and cash equivalents at end of period | $ | 1,417,069 | $ | 521,944 | $ | 1,417,069 | $ | 521,944 | |||||||
**
Reconciliation of Non-GAAP Financial Measures**
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below:
Scroll to view ↔
| Three Months Ended | Six Months Ended | ||||||||||||||
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | ||||||||||||
| Revenue | $ | 1,422,808 | $ | 1,282,089 | $ | 2,758,390 | $ | 2,506,598 | |||||||
| GAAP cost of sales | $ | 544,084 | $ | 530,814 | $ | 1,058,847 | $ | 1,038,104 | |||||||
| Less:Amortization of acquired intangibles(A) | (7,808 | ) | (7,634 | ) | (15,630 | ) | (15,304 | ) | |||||||
| Non-GAAP cost of sales | $ | 536,276 | $ | 523,180 | $ | 1,043,217 | $ | 1,022,800 | |||||||
| GAAP gross profit | $ | 878,724 | $ | 751,275 | $ | 1,699,543 | $ | 1,468,494 | |||||||
| GAAP gross margin | 61.8 | % | 58.6 | % | 61.6 | % | 58.6 | % | |||||||
| Non-GAAP gross profit | $ | 886,532 | $ | 758,909 | $ | 1,715,173 | $ | 1,483,798 | |||||||
| Non-GAAP gross margin | 62.3 | % | 59.2 | % | 62.2 | % | 59.2 | % | |||||||
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
Scroll to view ↔
| Three Months Ended | Six Months Ended | ||||||||||
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | ||||||||
| GAAP income from operations | $ | 491,660 | $ | 417,243 | $ | 938,195 | $ | 804,554 | |||
| Amortization of acquired intangibles—cost of sales_(A)_ | 7,808 | 7,634 | 15,630 | 15,304 | |||||||
| Amortization of acquired intangibles—operating expenses_(A_) | 11,764 | 11,047 | 23,721 | 22,451 | |||||||
| Restructuring_(A)_ | 5,935 | — | 21,745 | — | |||||||
| Non-GAAP income from operations | $ | 517,167 | $ | 435,924 | $ | 999,291 | $ | 842,309 | |||
**
Reconciliation of Non-GAAP Financial Measures**
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
Scroll to view ↔
| Three Months Ended | Six Months Ended | ||||||||||||||
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | ||||||||||||
| GAAP net income | $ | 392,593 | $ | 344,622 | $ | 741,129 | $ | 655,977 | |||||||
| Amortization of acquired intangibles—cost of sales_(A)_ | 7,808 | 7,634 | 15,630 | 15,304 | |||||||||||
| Amortization of acquired intangibles—operating expenses_(A)_ | 11,764 | 11,047 | 23,721 | 22,451 | |||||||||||
| Restructuring expenses_(A)_ | 5,935 | — | 21,745 | — | |||||||||||
| Income tax effect on non-GAAP adjustments_(A)_ | (6,627 | ) | (4,962 | ) | (15,875 | ) | (10,033 | ) | |||||||
| Non-GAAP net income_(A)_ | $ | 411,473 | $ | 358,341 | $ | 786,350 | $ | 683,699 | |||||||
| GAAP diluted shares outstanding | 146,372 | 147,481 | 146,633 | 147,520 | |||||||||||
| GAAP diluted earnings per share | $ | 2.68 | $ | 2.34 | $ | 5.05 | $ | 4.45 | |||||||
| Non-GAAP diluted earnings per share_(A)_ | $ | 2.81 | $ | 2.43 | $ | 5.36 | $ | 4.63 |
Scroll to view ↔
| (A) | Resmed adjusts for the impact of the amortization of acquired intangibles and restructuring expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. |
**
Revenue by Product and Region
**(Unaudited; $ in millions, except for per share amounts)
Scroll to view ↔
| Three Months Ended | |||||||||||
| December 31, 2025 | (A) | December 31, 2024 | (A) | % Change | Constant Currency_(B)_ | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 448.0 | $ | 414.5 | 8 | % | |||||
| Masks and other | 387.0 | 334.5 | 16 | ||||||||
| Total U.S., Canada and Latin America | $ | 835.0 | $ | 748.9 | 11 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 278.2 | $ | 254.8 | 9 | % | 5 | % | |||
| Masks and other | 142.7 | 121.8 | 17 | 8 | |||||||
| Total Combined Europe, Asia and other markets | $ | 420.9 | $ | 376.6 | 12 | 6 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 726.2 | $ | 669.3 | 9 | % | 7 | % | |||
| Total Masks and other | 529.7 | 456.3 | 16 | 14 | |||||||
| Total****Sleep and Breathing Health | $ | 1,255.9 | $ | 1,125.6 | 12 | 10 | |||||
| Residential Care Software | 166.9 | 156.5 | 7 | 5 | |||||||
| Total | $ | 1,422.8 | $ | 1,282.1 | 11 | 9 | |||||
Scroll to view ↔
| Six Months Ended | |||||||||||
| December 31, 2025 | (A) | December 31, 2024 | (A) | % Change | Constant Currency_(B)_ | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 861.5 | $ | 799.0 | 8 | % | |||||
| Masks and other | 748.3 | 657.3 | 14 | ||||||||
| Total U.S., Canada and Latin America | $ | 1,609.8 | $ | 1,456.3 | 11 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 545.0 | $ | 496.1 | 10 | % | 6 | % | |||
| Masks and other | 270.6 | 241.0 | 12 | 6 | |||||||
| Total Combined Europe, Asia and other markets | $ | 815.6 | $ | 737.1 | 11 | 6 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 1,406.5 | $ | 1,295.1 | 9 | % | 7 | % | |||
| Total Masks and other | 1,018.9 | 898.2 | 13 | 12 | |||||||
| Total****Sleep and Breathing Health | $ | 2,425.4 | $ | 2,193.3 | 11 | 9 | |||||
| Residential Care Software | 333.0 | 313.3 | 6 | 5 | |||||||
| Total | $ | 2,758.4 | $ | 2,506.6 | 10 | 8 |
Scroll to view ↔
| (A) | Totals and subtotals may not add due to rounding. |
| (B) | In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. |
Scroll to view ↔
| For investors | For media |
| +1 858-221-3304 | +1 619-510-1281 |
| [email protected] | [email protected] |
Source: Resmed, Inc.
Released January 29, 2026
©2026 ResMed Inc. All Rights Reserved.
Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding ResMed Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| LGHT | 9.11% | 1,156 | $ 225.281K | Jun 30, 2026 |
| CWS | 4.04% | 18,814 | $ 4.475M | Nov 17, 2026 |
| SEIQ | 2.04% | 69,334 | $ 13.512M | Jun 30, 2026 |
| FGSI | 1.95% | 167 | $ 39.835K | Nov 11, 2026 |
| RUNN | 1.88% | 32,577 | $ 7.822M | Aug 31, 2026 |
| RDVI | 1.53% | 250,021 | $ 59.638M | Nov 11, 2026 |
| XOVR | 1.36% | 152,376 | $ 29.695M | Jun 30, 2026 |
| QIDX | 1.26% | 2,325 | $ 490.529K | Jul 31, 2026 |
| ROE | 1.10% | 11,464 | $ 2.73M | Nov 18, 2026 |
| WLTG | 1.04% | 3,788 | $ 799.192K | Jul 31, 2026 |
| PY | 0.76% | 8,575 | $ 1.671M | Jun 30, 2026 |
| DSTL | 0.67% | 73,123 | $ 14.25M | Jun 30, 2026 |
| GQQQ | 0.62% | 4,283 | $ 1.02M | Nov 18, 2026 |
| IALT | 0.57% | 188,884 | $ 44.99M | Nov 16, 2026 |
| BAMV | 0.44% | 2,131 | $ 511.653K | Aug 31, 2026 |
| AVMC | 0.36% | 8,303 | $ 1.978M | Nov 16, 2026 |
| PHEQ | 0.28% | 2,012 | $ 392.099K | Jun 30, 2026 |
| BDVL | 0.26% | 19,225 | $ 4.579M | Nov 16, 2026 |
| JSTC | 0.26% | 3,246 | $ 773.165K | Nov 17, 2026 |
| TACU | 0.25% | 193 | $ 45.971K | Nov 17, 2026 |
| DFLV | 0.23% | 73,384 | $ 17.531M | Nov 12, 2026 |
| DAK | 0.22% | 384 | $ 90K | Nov 18, 2026 |
| CLSE short | -0.22% | -8,122 | $ -1.95M | Aug 31, 2026 |
| AIVL | 0.21% | 4,405 | $ 858.446K | Jun 30, 2026 |
| SOVF | 0.20% | 838 | $ 176.801K | Jul 31, 2026 |
| AFLG | 0.20% | 7,611 | $ 1.813M | Nov 16, 2026 |
| SFGV | 0.19% | 9,005 | $ 2.14M | Nov 18, 2026 |
| TIER | 0.14% | 225 | $ 47.471K | Jul 31, 2026 |
| CAPE | 0.13% | 1,571 | $ 306.156K | Jun 30, 2026 |
| DFVX | 0.12% | 3,011 | $ 719.298K | Nov 12, 2026 |
| GQI | 0.12% | 1,627 | $ 317.07K | Jun 30, 2026 |
| AVUQ | 0.12% | 2,153 | $ 512.823K | Nov 16, 2026 |
| GSPY | 0.12% | 3,583 | $ 853.435K | Nov 17, 2026 |
| DFUV | 0.11% | 74,325 | $ 17.755M | Nov 12, 2026 |
| DFSU | 0.11% | 10,903 | $ 2.605M | Nov 12, 2026 |
| GVLU | 0.09% | 1,038 | $ 247.241K | Nov 17, 2026 |
| XMAG | 0.08% | 684 | $ 163.401K | Nov 13, 2026 |
| THEQ | 0.07% | 112 | $ 26.677K | Nov 17, 2026 |
| VSLU | 0.06% | 1,699 | $ 331.101K | Jun 30, 2026 |
| MODL | 0.06% | 3,168 | $ 617.38K | Jun 30, 2026 |
| DFAU | 0.06% | 30,974 | $ 7.399M | Nov 12, 2026 |
| DXUV | 0.06% | 14,494 | $ 3.462M | Nov 12, 2026 |
| FLSP | 0.05% | 2,535 | $ 494.021K | Jun 30, 2026 |
| AVLC | 0.05% | 3,348 | $ 797.46K | Nov 16, 2026 |
| DFAC | 0.05% | 182,205 | $ 43.527M | Nov 12, 2026 |
| DFUS | 0.05% | 43,821 | $ 10.468M | Nov 12, 2026 |
| DCOR | 0.04% | 83,956 | $ 20.056M | Nov 12, 2026 |
| VOXP | 0.04% | 12 | $ 2,531.76 | Jul 31, 2026 |
| GDE | 0.04% | 849 | $ 203.845K | Aug 31, 2026 |
| AVUS | 0.04% | 26,148 | $ 6.228M | Nov 16, 2026 |
| AVSU | 0.04% | 804 | $ 191.505K | Nov 16, 2026 |
| APUE | 0.04% | 4,009 | $ 962.561K | Aug 31, 2026 |
| HCMT | 0.04% | 1,007 | $ 212.457K | Jul 31, 2026 |
| NTSX | 0.04% | 2,529 | $ 492.852K | Jun 30, 2026 |
| MSLC | 0.03% | 5,633 | $ 1.352M | Aug 31, 2026 |
| ACVF | 0.03% | 230 | $ 48.525K | Jul 31, 2026 |
| NTSD | 0.02% | 40 | $ 7,795.20 | Jun 30, 2026 |
| CSHP | 0.02% | 291 | $ 69.313K | Nov 16, 2026 |
| EBI | 0.01% | 159 | $ 38.176K | Aug 31, 2026 |
| CORO | 0.00% | 91 | $ 21.67K | Nov 16, 2026 |
